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ABSTRACT
Bipolar disorder, schizophrenia and schizoaffective disorder are extremely
debilitating illnesses that encompass affective and/or psychotic symptoms. Not 
only is there common symptomatology and genetic susceptibility, but the 
pharmacotherapy approaches are also similar. Nonetheless, molecular 
mechanisms underpinning these diseases are not yet fully understood. The theory 
that there is a dopaminergic dysfunction cannot account for all of the symptoms. 
Nor can the compounds that act on dopaminergic mechanisms successfully 
alleviate the symptoms. There is evidence to suggest that there are imbalances in
other neurotransmitter systems, particularly the main excitatory pathway - the
glutamatergic system. Glutamatergic transmission is essential for development, 
learning and memory and many other physiological functions of the brain. 
Glutamatergic receptors of the ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA)-type mediate the majority of the fast synaptic neurotransmission. 
Here, ????????? mice, lacking the GluA1 subunit of AMPA receptors, with 
concurrent schizophrenia-like and affective symptoms were used. The predictive 
validity was addressed using the standard and novel glutamate-modulating 
pharmacotherapeutics. The hyperactivity, the most robust feature of ?????????mice 
and a hallmark of psychotic disorders, was attenuated by drug-treatments.
Importantly, chronic treatments with lithium, valproate, topiramate, lamotrigine and
perampanel were effective, evidence of their pharmacological efficacy after the 
acute, often sedative, treatment phase. In addition, excessive novelty-induced 
activation of the dorsal hippocampus of ?????????mice as measured by c-Fos 
expression was blunted by the drug-treatments of which all are known to reduce 
the activity of the glutamatergic transmission. Other behaviours relevant to the 
schizoaffective symptomatology such as disinhibited risk-taking, less despair-like 
behaviour and highly exploratory phenotype as well as social deficits were partially 
responsive to treatment with mood-stabilisers. Moreover, ?????????mice exhibited 
a slightly higher preference for sucrose and made more impulsive choices towards 
sucrose. The ?????????mice may represent a suitable model for the screening of 
the preclinical efficacy of novel drugs on the hyperactive behaviour linked to manic 
episode of bipolar disorder, schizophrenia and schizoaffective disorder. 
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ABBREVIATIONS
5-HT                      5-hydroxytryptophan, serotonin
AMPA ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA                  analysis of variance
BPD bipolar disorder 
CA cornu ammonis of hippocampus
CaM kinase II Ca2+/calmodulin-dependent kinase II 
CeL central nucleus of amygdala, lateral
DA dopamine 
DG dentate gyrus 
EAAT excitatory amino acid transporters 
EPM elevated plus maze 
FST forced swimming test 
GABA ?-aminobutyric acid
GSK-3                   glycogen synthase kinase-3
IEG immediate early gene
IP3 1,4,5-trisphosphate 
LA locomotor activity 
LTP long-term potentiation 
mGluR metabotropic glutamate receptor 
NMDA N-methyl-D-aspartate
NP                         nose-poke 
NSF N-ethylmaleimide sensitive fusion protein 
PFC prefrontal cortex 
PICK1 protein interacting with C kinase 1 
PKC protein kinase C 
PLC phospholipase C 
PPI pre-pulse inhibition 
PSD post-synaptic density protein 
RW running wheel 
SAD schizoaffective disorder
SCZ                  schizophrenia
Ser serine
TARP                     transmembrane AMPA receptor regulatory protein
TST tail suspension test
V                           visit
VTA ventral tegmental area 
WT wild-type line
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1. INTRODUCTION
The amino acid glutamate is the major constituent of the neurotransmitter system 
in our brain that mediates an excitatory signal from presynaptic to postsynaptic 
neurons. Glutamatergic neurotransmission is fundamentally involved in the 
neuroplasticity occurring in development as well as in learning and memory. In the 
1980s however, the glutamatergic system was also recognised to exert a role in 
psychiatric conditions since the compounds blocking the N-methyl-D-aspartate 
(NMDA) type of glutamatergic ionotropic receptors evoked psychotic symptoms 
resembling those encountered in schizophrenia (SCZ). This formed the basis of 
the glutamatergic theory of schizophrenia and this initiated an era of investigations 
attempting to clarify how the glutamatergic system could function in conjunction 
with the previous theory of dopaminergic dysfunction. Subsequently, numerous 
studies of patients with SCZ, bipolar disorder (BPD) and schizoaffective disorder 
(SAD) identified abnormalities in glutamatergic transmission in their 
pathophysiology. Thereafter, the glutamatergic system has become an attractive 
target for pharmacological treatments, via a modulation of the availability of the 
glutamate in the synapse, its removal from synaptic sites or modulation of its 
receptors. A lack of patient response to standard treatments and recurrences of 
symptoms highlight the clear need for the development of novel therapeutics
(Gitlin, 2006; Smith et al., 2007; Tohen et al., 2005). This is particularly true since
these diseases pose a substantial economic burden to the global healthcare 
systems and society as a whole due to the chronic course, early onset, excess 
mortality, remissions and probability of the severe level of disability (Wu et al., 
2005). 
Animal models are invaluable tools for unravelling mechanisms of 
psychiatric diseases, evaluating drug targets and designing selective new drugs.
Unfortunately, in neuropsychiatric research, definitive animal behavioural 
correlates of human conditions are unattainable. However, there are two key 
approaches towards creating valid animal model. First is to use a model based on
risk factors (such as genetic or environmental) relevant to the pathophysiology of 
human disease. Second, an assessment of phenotype can be undertaken with a
comprehensive set of tests that have cross-species validity. The use of these 
models can lead to identification of drug candidates with greater translational
value. Alternatively, their use may lead to the discovery or the development of 
improved therapeutics.
The unclear etiology, clinical heterogeneity, cyclic nature of disease and 
unknown biomarkers/endophenotypes for evaluating treatment outcomes 
represent additional challenges for modelling of BPD, SCZ and SAD. However, as
our understanding grows of the role of the glutamate in these diseases, it may be 
possible to generate novel glutamate-modifying therapeutics and real 
breakthroughs as disease-modifying agents. 
9
2. REVIEW OF LITERATURE
2.1 NEUROTRANSMITTER GLUTAMATE: SYNTHESIS, PACKAGING AND 
TRANSPORT
After its release from the presynaptic neuron, glutamate triggers depolarization 
of postsynaptic membrane and subsequently activates the postsynaptic neuron. 
This is in direct opposition to the GABAergic effect that hyperpolarises post-
synaptic neuron; together, these two systems mediate the majority of excitatory 
and inhibitory transmission. 
Glutamate is formed ????? ?-ketoglutarate, an intermediate in the metabolic 
pathway known as tricarboxylic acid cycle (TCA) or Krebs cycle (Albrecht et al., 
2007). The effect of glutamate is terminated by its re-uptake from the synaptic cleft 
into astrocytes, the glial cells expressing excitatory amino acid transporters 
(EAAT) (Slotboom et al., 1999). There, the enzyme glutamine synthetase converts 
glutamate to glutamine, which lacks neurotransmitter properties and this is then 
exported back to neurons. Neurons in turn have the ability to deamidate glutamine
via phosphate-activated glutaminase (Akiyama et al., 1990), and the resynthesized 
glutamate is then taken up and stored into vesicles. There may also exist one 
other, glutamine-independent mechanism of production of glutamate in the 
neurons (Hassel and Brathe, 2000)??????? ??????????????????????????-ketoglutarate 
and counter-down action of neuronal pyruvate carboxylase to replenish TCA cycle 
with malate, a precursor of oxaloacetate. In GABAergic neurons, there is a one-
step reaction of glutamate decarboxylase, which converts glutamate into GABA 
(Martin and Rimvall, 1993).
Inside the neurons, the neurotransmitter glutamate is concentrated into 
synaptic vesicles by vesicular glutamate transporters, of which three forms are 
currently known (VGLUT I-III) (Fremeau et al., 2002; Kaneko and Fujiyama, 2002).
Their expression on GABAergic, cholinergic and monoaminergic neurons raised 
some doubts about them being specific to glutamatergic neurons (Fremeau et al., 
2004).
Although it is involved in mediating many fundamental processes, the effects of
glutamate at times can be detrimental and therefore are tightly controlled (Mark et 
al., 2001). The rapid removal of glutamate from the extracellular space is crucial 
for the optimal function of synapse and prevention of postsynaptic overstimulation. 
This is achieved by a family of high-affinity EAAT transporters (Danbolt, 2001).
EAAT2 is the principal transporter in the forebrain and this protein is present in 
both astrocytes and neurons. EAAT1 is only found in astrocytes; it is abundant in 
the cerebellum and present in the forebrain. EAAT3 is expressed in neurons in the 
whole brain (Conti et al., 1998); EAAT4 is largely expressed on dendrites of 
cerebellar Purkinje cells (Yamada et al., 1996), whereas EAAT5 is expressed in 
the retina (Bringmann et al., 2009). In the rat EAAT1–3 are termed GLAST, GLT 
and EAAC1, respectively. 
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Several sites at the glutamatergic synapse are being exploited for 
pharmacotherapy: modulation of glutamate transport back to astrocyte, or 
packaging into vesicles and release, or presynaptic release or voltage-dependent 
Na+ channel modulation that affect glutamate release. Additionally, one further site 
of modulation is located at the receptor level.  
2.2 GLUTAMATE RECEPTORS
Glutamate receptors are classified into two major categories, ionotropic (AMPA, 
NMDA, kainate and delta) and metabotropic (mGluR), depending on whether ion 
channels or second messenger system transduce the glutamate signal, 
respectively (Table 1, 2). Ionotropic receptors are assembled from four subunits 
that surround a central pore: GluA1–GluA4 for ?-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid  (AMPA) (formerly GLUA1-A4, GluR1-4, GluRA-D), GluK1–
GluK5 for kainate (formerly GLUK5-K7 and GLUK1-K2, GluR5-7 and KA1-2, GluR5-7
and KA-1-2), GluN1, GluN2A-2D and GluN3A-3B for NMDA receptors (formerly 
GLUN1, GLUN2A-2D and GLUN3A-3B, NMDA-R1, NMDA-R2A-2D and NMDA-R3A-3B, 
and NR1, NR2A-2D and NMDAR-L) and GluD1-D2 subunits for the recently 
characterized delta receptors (see Collingridge et al., 2009 for detailed 
nomenclature of ionotropic receptors). Depending on the subunit composition, 
ionotropic receptors can conduct fluxes of Na+ and Ca2+. Each subunit consists of 
four different domains: amino-terminal, ligand-binding, transmembrane and 
carboxyl-terminal domain. Metabotropic receptors (mGluR1-8) are G protein-
coupled receptors, and their effects can be either inhibitory or stimulatory, 
depending on the G protein that they recruit. 
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Table 1. Ionotropic glutamate receptors.
Receptor Subunit composition Action
Transduction 
mechanism Localization
Pharmacology
(Examples)
NMDA GluN1 
GluN2A 
GluN2B 
GluN2C 
GluN2D 
GluN3A 
GluN3B
Excitatory    Na+
Ca2+
Postsynaptic
Extrasynaptic
Agonists: glycine, D-Serine,
alanine, glutamate, aspartate
Antagonists:
- Competitive: AP5, CPP               
- Noncompetitive: ifenprodil
- Uncompetitive: 
ketamine, phencyclidine
Positive allosteric modulators:
neurosteroids
AMPA GluA1                
GluA2                
GluA3                
GluA4
Excitatory    Na+
(Ca2+)
Postsynaptic
Extrasynaptic
Agonists: glutamate, AMPA, 
kainate
Antagonists:
- Competitive: CNQX, NBQX         
- Noncompetitive: CP-465,022,
GYKI 53655, perampanel
- Uncompetitive: 
argio-, philantho- toxins
Positive allosteric modulators: 
aniracetam, ampakines,
cyclothiazide
Kainate GluK1 
GluK2 
GluK3 
GluK4 
GluK5
Excitatory    Na+
(Ca2+)
K+
Presynaptic 
Postsynaptic
Agonists: glutamate, AMPA, 
kainate
Antagonists:
- Competitive: CNQX, NBQX
- Noncompetitive: GYKI 52466
- Uncompetitive: joro spider -toxin
Delta GluD1 Excitatory    Na+
(Ca2+)
Inner hair cells 
of the organ of 
Corti; Highly 
expressed in 
forebrain
GluD2 Enriched in 
cerebellum
Antagonists: pentamidine
2.2.1 AMPA RECEPTORS
The activation of AMPA receptor produces excitatory postsynaptic potentials 
(EPSPs). The activation of AMPA receptors is fast and transient, causing very 
brief depolarisations that last no longer than a few milliseconds in contrast to a 
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slower rise time and decay of the NMDA component. Unlike their counterparts 
NMDA, AMPA receptors are crucial for basal synaptic transmission, and structural 
and functional modifications at AMPA receptors are actively involved in several 
stages of synaptic strengthening and long-term potentiation and depression that 
are the correlates of memory formation. See section 2.8 for more details on the 
properties of the AMPA receptors.
2.2.2 NMDA RECEPTORS
Most of the functional NMDA receptors are heteromeric, requiring two GluN1 
subunits together with either two GluN2 or a combination of GluN2 and GluN3 
subunits (Monyer et al., 1992; Schorge and Colquhoun, 2003; Ulbrich and Isacoff, 
2007). Expression of GluN1 is almost ubiquitous in central nervous system,
whereas the distribution of the other subunits displays a more distinctive pattern of 
expression. GluN2A and GluN2B are present in forebrain, GluN2A and GluN2C in 
cerebellum and GluN2D is present in midbrain and hindbrain. GluN3A is mainly 
found in spinal cord and cortex whereas GluN3B can be detected in motor 
neurons in the spinal cord, pons and medulla. There are numerous regulatory sites 
present on the NMDA receptors, e.g. recognition sites for two different agonists 
(glycine and glutamate) and polyamine regulatory site both of which trigger ion flux 
through receptor. There are also separate sites for Mg2+, Zn2+ and H+ that inhibit 
receptor activation (Dingledine et al., 1999; Mayer, 2005). The NMDA receptors 
possess several unique properties; their affinity for glutamate is high and it 
displays very slow kinetics of (de)activation. The activation of the receptor exhibits 
an unusual co-agonistic action: simultaneous binding of glycine to GluN1 and 
glutamate to GluN2 is required (Johnson and Ascher, 1987). Another brake on its 
activation is provided by extracellular Mg2+, which exerts a voltage-dependent 
block on the open ion channel (Nowak et al., 1984). The H+ ion is a potent inhibitor 
of NMDA receptors activation which may be especially important in pathological 
conditions such as acute stroke and other acidosis conditions. The long time-
course of NMDA receptors activation provides an opportunity for temporal and 
spatial summation of multiple inputs. These specificities permit the NMDA receptor 
to act as a perfect coincidence detector: large depolarization and synaptic release 
of glutamate are both required to allow permeation of calcium (Ca2+) ions through 
the ion pore (Seeburg et al., 1995). The high Ca2+ permeability makes possible the
interaction of Ca2+ ions with calcium-dependent enzymes, second messengers, 
protein kinases and phosphatases, scaffolding proteins, cytoskeletal elements, 
GTP binding proteins and their regulators, and adhesion molecules which then 
transform the synaptic inputs into long-lasting cellular modifications. 
In addition to glycine, the D- and L-isomers of serine and alanine can act as
agonists at the GluN1 subunit.  The agonists at GluN2 are typically short-chain 
dicarboxylic amino acids, such as glutamate, aspartate and NMDA itself although 
it is several-fold less potent than glutamate (Table 1). If one extends the length of 
the glutamate carbon chain, then one can obtain several competitive antagonists 
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at the glutamate recognition site (Traynelis et al., 2010). Numerous competitive 
antagonists are available (Table 1), such as D-2-amino-5-phosphonopentanoic 
acid, which traditionally has been used for distinguishing the NMDA from the 
responses mediated via AMPA and kainate receptors.  The selectivity of the 
GluNR2 subunit is difficult to achieve but it could be one way to develop
compounds with distinct therapeutic potential and side effects. The first subunit-
selective NMDA receptor antagonist, ifenprodil, introduced a new class of 
noncompetitive antagonists of GluN2B-containing NMDA receptors; this 
compound binds at a site distinct from the glutamate- and glycine-binding sites 
(Hess et al., 1998). The compounds that block NMDA receptor channels via use-
dependent and voltage-dependent mechanism such as the dissociative 
anaesthetics, phencyclidine (PCP) and ketamine are uncompetitive antagonists 
(Table 1). They slowly dissociate from their binding site in the NMDA receptor 
channel and may become trapped in the pore (‘trapping blockers’) which are 
features that complicate their safety profile.
2.2.3 KAINATE RECEPTORS
GluK1–GluK3 subunits form homomers or heteromers, or they co-assemble with 
GluK4 or GluK5, which are otherwise inactive on their own (Lerma, 2003;
Traynelis et al., 2010). As with the AMPA receptors, mRNA editing at the Q/R site 
reduces divalent cation permeability and channel conductance. In the mossy fiber-
CA3 pyramidal cell synapse, the most extensively studied site of kainate receptor-
mediated synaptic transmission, GluK2 and GluK5 are located postsynaptically, 
whereas GluK1 to GluK3 are present presynaptically. In that way, they are able to
mediate a wide range of functions, e.g. postsynaptic depolarization at a subset of 
excitatory synapses, presynaptic modulation of both excitatory and inhibitory 
transmission and refinement of synaptic strength during development (Contractor 
et al., 2011). The clarification of their role was delayed due to the lack of 
antagonists selective for kainate over AMPA receptors but recently some agents
have been developed (Table 1)(Sakai et al., 2001; Zhou et al., 1997). Given the 
role of kainate receptors in mediating epileptiform activity, it would be interesting to 
identify agents that could selectively target the kainate receptor subunits in this 
pathophysiological condition (Vincent and Mulle, 2009).
2.2.4 DELTA RECEPTORS
This orphan family is characterised by its sequence homology with the ionotropic 
family subunits, however, they are unresponsive to glutamate which makes it 
difficult to determine their functional roles (Lomeli et al., 1993; Yamazaki et al., 
1992). They consist of the GluD1 and GluD2 receptors that share 60% homology 
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(Table 1). GluD2 is selectively expressed in the parallel fiber-Purkinje cell synapse 
and it associates with the mGluR1 in the cerebellum (Takayama et al., 1996); a 
loss of GluD2 in this region has been linked with impairment in motor learning and 
severe ataxia. The deletion of GluD1 causes a hearing deficit in mice as GluD1 is 
highly enriched in the inner hair cells of the organ of Corti (Gao et al., 2007;
Safieddine and Wenthold, 1997).
2.2.5 METABOTROPIC RECEPTORS
Three functional classes of mGluRs exist based on amino-acid sequence 
homology, agonist pharmacology and the signal transduction pathways to which 
they are coupled (Table 2). Group I includes mGluR1 and mGluR5, group II 
includes mGluR2 and mGluR3, and group III includes mGluR4, mGluR6, mGluR7 
and mGluR8. It is known that alternatively spliced variants exist for mGlu1, mGlu4, 
mGlu5 and mGlu7 (Kew and Kemp, 2005). The group I mGluRs couple with Gq
protein, stimulate phospholipase C (PLC) activity to produce 1,4,5-trisphosphate 
(IP3), further releasing the Ca2+ from cytoplasmic stores, as well as diacylglycerol, 
which activates the enzyme PKC. The activation of the group II and III mGluRs 
results in inhibition of adenylate cyclase through Gi/o protein. 
The mGluRs are localised in both neurons and glia and they are present in 
both pre- (group II and III) and postsynaptic sites (group I) (Lujan et al., 1996;
Pinheiro and Mulle, 2008). Postsynaptic mGluR activation triggers an excitatory 
response, whereas presynaptic mGluR activation blocks synaptic transmission. 
For example, the inhibition of voltage-dependent Ca2+ channels, the activation of 
potassium (K+) and/or the inhibition of the exocytotic processes downstream from 
calcium entry (Conn and Pin, 1997) would exert negative feedback to ensure that
the glutamate transmission remains within the physiological range.
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Table 2: Metabotropic glutamate receptors (Modified from Swanson et al., 2005).
Subtype Structure Action Transduction mechanism Localization
Pharmacology
(Examples)
GROUP I
mGluR1        
mGluR5
G protein-
coupled 
receptors
(seven 
transmembrane 
domain)
Increase 
excitability   
(Gq-
coupled)
Activation of 
PLC 
(increase 
Ca2+, IP3)
Postsynaptic at 
glutamatergic 
synapses; mGluR5 
also in glial cells 
mGluR1: Required 
for LTD in  cerebellar 
synapses 
mGlu5: Highly 
expressed in 
forebrain                       
Agonists: DHPG, 1S,3R-
ACPD, CHPG (mGluR5)
Antagonists: LY393675
Inverse agonist
(or allosteric antagonist):
LY367385 (mGluR1), 
MPEP (mGluR5)
GROUP II
mGluR2
mGluR3 
                      
G protein-
coupled 
receptors
(seven 
transmembrane 
domain)
Decrease 
excitability   
(Gi/o-
coupled)
Inhibition of 
adenylate 
cyclase;
Inhibition of 
voltage-
gated-
Ca2+channels;
Activation of 
K+ channels
Presynaptic 
regulation of 
glutamate and GABA 
release, also  
postsynaptic                 
mGluR2: Highly 
expressed in 
forebrain
mGluR3: Widely 
expressed in glial 
cells
Agonists: DHPG, 1S,3R-
ACPD, LY354740
Antagonists:
LY341495
GROUP III
mGluR4
mGluR6
mGluR7
mGluR8   
                      
G protein-
coupled 
receptors
(seven 
transmembrane 
domain)
Decrease 
excitability   
(Gi/o-
coupled)
Inhibition of 
adenylate 
cyclase; 
Inhibition of 
voltage-
gated-
Ca2+channels;
Activation of 
K+ channels
Pre- (mGluR4, 7, 8) 
and post-synaptic 
(mGluR4, 7) on 
glutamatergic and 
other systems
mGluR6: Only in the 
retina
mGluR4:Highly 
expressed in 
cerebellum
mGluR7: Has lower 
affinity for glutamate 
than other subtypes 
mGluR8: Highly 
expressed in 
forebrain
Agonists: L-AP4, ACPT-1
(mGluR4), 3,4-DGPG 
(mGluR8)
Antagonists: MSOP, CPPG 
(mGluR4), LY341495 
(mGluR7; 100-fold lower
affinity than group II)               
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2.3 AMPA RECEPTOR PROPERTIES
2.3.1 LOCALISATION OF AMPA RECEPTORS
The mRNAs encoding GluA1-A4 protein subunits of AMPA receptors are 
abundantly present in the central nervous system, as detected by in situ
hybridisation and immunohistochemical methods; hippocampal formation, the 
cortical regions, the basal ganglia, the olfactory bulbs and the amygdala are 
particularly enriched with these receptors (Keinanen et al., 1990; Petralia and 
Wenthold, 1992). The principal AMPA channels at excitatory neurons are 
heteromers comprised of the GluA2 subunit and one of the GluA1, GluA3 or GluA4
subunits. The homomers of GluA1 are located on inhibitory neurons whereas 
those of GluA3 and GluA4 receptors are present at only low levels (Fleming and 
England, 2010; Keinanen et al., 1990). The expression of the GluA2 subunit 
determines Ca2+ permeability and its levels increase throughout the early postnatal 
period. 
AMPA receptors are found at synaptic, extrasynaptic and intracellular sites. 
Synaptic receptors are predominantly GluA1A2-containing (about 80%) (Beique 
and Huganir, 2009; Lu et al., 2009) with the remaining receptors being GluA2A3-
containing. There are extrasynaptic receptors, which are overwhelmingly GluA1A2 
heteromers, and in conjunction with the intracellular receptors, they form a reserve 
pool for trafficking of AMPA receptor into and back out of synapses (see chapter 
2.3.5 below for more details on this topic). The composition of AMPA receptor 
subtypes is an important aspect of synaptic plasticity.
2.3.2 SYNTHESIS OF AMPA RECEPTORS
Individual subunits are synthesized in the cell body and the assembly of the 
channel continues in the endoplasmic reticulum. Palmitoylation, a posttranslational
modification, is important for ensuring correct trafficking of the AMPA receptor 
(Hayashi et al., 2005) and this process occurs in the Golgi. However, subunits can 
also be synthesized locally in dendrites from mRNA that has been transported
from the cell body. Indeed, all of the required translational machinery and Golgi 
are present in dendrites. The local synthesis of AMPA receptor subunits 
apparently maintains local receptor abundance and composition (Ju et al., 2004).
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2.3.3 STRUCTURE OF AMPA RECEPTORS
The amino-terminal domain is made up of a large number of amino acids of each 
subunit of the AMPA receptor, but has a more regulatory role and it is not essential 
for receptor function (O'Brien et al., 1999) (Fig. 1). Receptor heterogeneity is 
achieved in this domain by alternative splicing and mRNA editing (Traynelis et al., 
2010). The flip and flop splice variants differ in 11 amino acids in the extracellular 
loop between the transmembrane M3 and M4 segments and these changes
influence the rate of receptor desensitisation and regional distribution. The 
expression of these variants is dependent on the developmental stage i.e. the flip 
form is present in prenatal AMPA receptors whereas the numbers of the flop 
variant increase postnatally (Monyer et al., 1991). RNA editing, located near the 
flip/flop splicing site, results in a change from arginine to glycine (R/G) in the 
GluA2-GluA4 subunits (Lomeli et al., 1994), which modifies the desensitisation
properties of the receptors. The edited G forms recover more quickly from 
desensitisation. The ligand-binding domain lies in clamshell-like gorge formed by 
two lobes, S1 and S2. Agonist binding causes a partial closure of the clamshell 
and opens the pore. The channel-lining M2 domain, which harbours the Q/R site, 
has an unusual re-entrant loop with both ends facing the cytoplasm.  The ‘Q/R site’ 
determines Ca2+ permeability. If glutamine (Q) resides in this position as is the 
case in GluA1, GluA3 and GluA4, the channel is permeable to Ca2+, but if arginine 
(R) is present as in GluA2, it does not permit the Ca2+ to pass through the channel.
Since the GluA2 subunit is predominantly found in most of the AMPA receptors, 
they are impermeable to Ca2+. In fact, increased AMPA fluxes due to the 
appearance of Ca2+ permeable, GluA2-lacking receptors are found not only in 
some pathological conditions such as cerebral ischaemia (Gorter et al., 1997) and
epilepsy (Friedman et al., 1994; Prince et al., 1995) but also after drug-induced 
potentiation in the glutamatergic synapses on ventral tegmental area (VTA)
dopamine (DA) neurons (Vashchinkina et al., 2012). The carboxyl-terminal domain 
is important for binding with the proteins that influence receptor modification and 
trafficking. There is also another alternative splicing called the “short” and “long” 
splice variants in GluA1, GluA2 and GluA4 subunits (Kohler et al., 1994). An 
additional mechanism for tuning of the receptor is achieved via a number of 
transmembrane proteins. Transmembrane AMPA receptor regulatory proteins 
(TARPs) and cornichon homologs regulate gating, ion permeability, pharmacology 
and trafficking of the receptor (Traynelis et al., 2010).
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Figure 1. Structure of the AMPA receptor subunits and the tetrameric channel. The channel 
consists of four subunits, which are usually two dimers of two different subunits, such as GluA1 
and -2 or GluA2 and -3. The individual subunits are composed of four transmembrane domains. 
The N-terminal domain lacks a clear functional role. Two alternatively spliced versions, flip and 
flop, influence the pharmacological and kinetic properties of the channel and form part of the 
extracellular ligand-binding domain. Editing of a glutamine codon to an arginine codon (Q/R 
editing site) in the ion channel pore region regulates the calcium permeability. The AMPA 
receptor C-termini differ in their amino acid sequence, and this determines the nature of their 
interacting partners. Modified from Shepherd and Huganir, 2007.
2.3.4 PHARMACOLOGY OF AMPA RECEPTORS
Quinoxalinediones are widely used competitive AMPA receptor antagonists 
(CNQX, DNQX, NBQX), which are selective in the sense that they do not bind to
NMDA receptors but they do antagonise kainate receptors; NBQX seems to have 
greater selectivity for AMPA receptors (Wilding and Huettner, 1996) (Table 1). 
Noncompetitive antagonists at AMPA receptors have been used to selectively 
target AMPA but not kainate receptors, including 2,3-benzodiazepines and 1,2-
dihydrophthalazines, as well as tetrahydroisoquinolines (Gitto et al., 2003), with 
CP-465,022 apparently showing greater selectivity than GYKI-53655 for AMPA in 
preference to kainate receptors (Lazzaro et al., 2002). The subsequent generation 
of noncompetitive AMPA antagonist, perampanel and talampanel, have been 
reported to be highly selective for AMPA receptors (Rogawski and Hanada, 2013;
Swanson, 2009) (Table 1). Perampanel has been recently approved for the 
treatment of partial onset seizures. Since the ligand-binding domain sequence is 
highly conserved among all four GluA subunits, currently there is no agonist 
possessing subunit selectivity, even though some of these compounds were 
developed to discriminate between GluA1/GluA2 and GluA3/GluA4 subunits
(Coquelle et al., 2000). Furthermore, the association of AMPA receptors with 
TARPs affects agonistic affinity (Kott et al., 2007; Turetsky et al., 2005), a property 
which was underestimated in in vitro studies. Positive allosteric modulators 
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(aniracetam, piracetam, ampakines, cyclothiazide) were developed in attempts to 
prevent the desensitisation state i.e. the phenomenon when agonist remains 
bound but the channel is closed. 
2.3.5 AMPA RECEPTOR TRAFFICKING
AMPA receptors are continuously being trafficked (endocytosed, recycled, and 
reinserted) into and out of the plasma membrane in a regulated and a constitutive 
manner (Malenka, 2003). In the regulated pathway, GluA1-containing AMPA 
receptors are trafficked to the synapse in an activity-dependent manner, which is 
stimulated by NMDA receptor activation. In contrast, GluA1-lacking AMPA 
receptors, usually GluA2A3 heteromers are being trafficked constitutively. These 
two pathways are governed by the interactions between the carboxyl-terminal 
domain of subunit and various synaptic compounds and proteins. The short C-tails 
of GluA2/3 receptors allow them to be inserted directly into the post-synaptic 
density protein (PSD) in an interaction with N-ethylmaleimide sensitive fusion 
protein (NSF), which dissociates GluA2 from protein interacting with C kinase 1 
(PICK1). The presence of long C-tails prevent GluA1/4 receptors from being 
inserted directly into the synapse in the absence of activity and in fact they are first 
inserted at extrasynaptic adjacent sites and laterally diffuse to synapses (Borgdorff 
and Choquet, 2002; Passafaro et al., 2001). The constitutive pathway maintains
total number of synaptic AMPA receptors, and the regulated pathway is evoked 
transiently upon the induction of synaptic plasticity.
2.3.6 THE POSTSYNAPTIC DENSITY 
NMDA and AMPA receptors are located extensively across the postsynaptic 
density (PSD), whereas mGluRs (except mGluR7) are concentrated along the 
periphery of the PSD. PSD is a protein complex containing machinery for 
transduction of the signal from receptors into various intracellular signal pathways
(Fig. 2). Thus, the PSD can be considered to consist of ion channels, glycolytic 
enzymes, transporters, proteins of intracellular signaling pathways, cell adhesion 
molecules and the scaffolding proteins that link together the proteins of the PSD 
(Kennedy, 2000; Walikonis et al., 2000).
One major scaffolding protein of the PSD is PSD95 that is anchored to the lipid 
rafts via palmitic acid residues (Fig. 2). This protein has several domains through 
which it can bind to other proteins: PDZ domain (short for PSD95/disc large/zona 
occludens-1) that binds C-termini of other proteins, the Src homology domain, and 
the guanylate kinase domain. PSD95 anchors the NMDA receptor via PDZ domain 
to the cytoskeleton of the dendritic spine and couples it to the signaling effector 
cascade. The Ca2+ that has entered into the postsynaptic cell after NMDA receptor 
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activation interacts with protein calmodulin and activates a protein kinase, 
Ca2+/calmodulin-dependent kinase II (CaM kinase II)?? ??? ??? ?????? ????-actinin via 
the scaffolding protein densin. The target of this PSD abundant kinase is the 
serine (Ser) residue 831 of the GluA1 subunit of the AMPA receptor. This 
phosphorylation increases the conductance of the AMPA receptor, which is one 
mechanism that contributes to the potentiation of glutamatergic synapses (Palmer 
et al., 2005). Another important phosphorylative modification of GluA1 subunit is 
catalysed by PKA and PKC that are anchored by scaffolding protein A-kinase 
together with protein phosphatase calcineurin to the Src homology domain and the 
guanylate kinase domains of PSD95 (Fig. 2). Phosphorylation of GluA1 on Ser845 
by PKA recruits to a variable degree more of AMPA receptors, which are located 
intracellularly in recycling endosomes, to the plasma membrane of the dendritic 
spine. PKC phosphorylates other serine residues on GluA1 (Ser816 and Ser818) 
enabling GluA1 to travel along actin filaments to the plasma membrane. On the 
other hand, Ca2+-dependent activation of the phosphatase calcineurin, which 
dephosphorylates GluA1 on Ser845, would lead to relocation of AMPA receptors 
from the plasma membrane to the cytosol and long-term depression (Collingridge 
et al., 2010). The entry of Ca2+ may also activate nitric oxide synthase and 
adenylate cyclase (Fig. 2).
Stargazin and other members of TARP family provide an indirect link between
AMPA receptors and PSD95. Other PSD proteins with PDZ domains can directly 
interact with the C termini of AMPA receptors. The GluA2/3 subunits interact with 
the glutamate receptor-interacting protein and AMPA receptor-binding protein 
(Dong et al., 1997; Srivastava et al., 1998). The GluA2, -3, and -4 bind with PICK1 
(Xia et al., 1999), while GluA1 interacts with synapse-associated protein of 97 kDa 
(Leonard et al., 1998).
Scaffolding proteins Homer and Shank anchor metabotropic glutamate 
receptors to the periphery of the PSD (Tu et al., 1999). In addition, Homer is also 
the link connecting mGluRs to the IP3 receptor (Fig. 2). In this way, IP3 released 
upon stimulation of type I mGluRs reaches the IP3 receptor.
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Figure 2. Schematic representation of a dendritic spine of a glutamatergic synapse with some 
proteins of the postsynaptic density. Lipid rafts, scaffolding proteins (such as PSD95, GRIP, Shank and 
Homer) and cytoskeletal proteins (F-actin) help to concentrate and stabilize effector proteins at the spine. 
Adenylate cyclase (AdCyc), A-kinase anchoring protein (AKAP), AMPA receptor, Ca2+/calmodulin-dependent 
kinase II (CaMK II), calcineurin (CaN), diacylglycerol (DAG), filamentous actin (F-actin), glutamate receptor-
interacting protein (GRIP), inositol-1,4,5-triphosphate (IP3), metabotropic glutamate receptor (mGluR), NMDA
receptor, nitric oxide synthase (NOS), protein kinase A and C respectively (PKA and PKC), phospholipase C
(PLC), postsynaptic density protein with a molecular weight of 95 kDa (PSD95); smooth endoplasmic reticulum
(SER). Modified from Brady et al., 2012.
2.4 GLUTAMATE IN NEUROPSYCHIATRIC DISORDERS 
Since the glutamate is the major excitatory transmitter, its proper functioning is 
fundamental for the brain i.e. in growth, development and cognition. In the last 
decades, there are several lines of evidence pointing to the altered glutamatergic 
transmission in mood and psychotic disorders, however. Brain glutamate levels 
are higher in bipolar manic patients and in those with SCZ than in healthy subjects
as measured by in vivo by proton magnetic resonance spectroscopy (Gigante et 
al., 2012; Poels et al., 2014); the higher glutamate levels are independent of the 
current state, with a tendency towards reduction in response to medication. The 
analysis of the post-mortem frontal cortex of these patients revealed markers of 
excitotoxicity and neuroinflammation (Rao et al., 2010). Furthermore, genetic 
studies pointed to polymorphisms of GluN1 and GluN2 subunits of NMDA
receptors with regard to mood disorders and SCZ and reduced expression of 
NMDA receptor subunits has been demonstrated (Kristiansen et al., 2007).
Although there are several subunits of AMPA-type glutamate receptors, decreased 
expression of the GluA1 subunit has been observed in the post-mortem 
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hippocampus, thalamus and frontal cortex of schizophrenic patients (Dracheva et 
al., 2005; Eastwood et al., 1997; Eastwood et al., 1995; Harrison et al., 1991;
Ibrahim et al., 2000; Sokolov, 1998) and in the striatum of bipolar patients 
(Meador-Woodruff et al., 2001).
The pharmacological blockade of NMDA receptors with PCP or ketamine 
serves as a commonly used rodent model of psychosis. Mechanistically, hypo-
function of NMDA receptors would presumably decrease inhibitory tone and favour 
cortical over-excitation (resulting in stimulation of non-NMDA glutamate receptors) 
that could induce psychotic-like symptoms (Moghaddam et al., 1997). The 
symptoms are reversible by administration of agonists of group II mGluRs that act 
on presynaptic inhibitory autoreceptors and reduce excess glutamate release 
(Krystal et al., 1999; Moghaddam and Adams, 1998), or with an antagonist of 
AMPA receptors (Moghaddam et al., 1997). Even though there was convincing
preclinical evidence, one clinical study of mGluR2/3 receptor agonist in SCZ was 
discontinued (Kinon et al., 2011; Stauffer et al., 2013), since no benefits were seen 
with the tested compound over standard antipsychotic therapy.  
Indeed, many drugs that are used as mood-stabilisers and anticonvulsants are 
glutamate-modifying agents (Table 3). They have recognized effects on
presynaptic release of glutamate, act on synaptic cleft, change the binding of 
glutamate to its receptors or regulate its transport. By blocking the use-dependent 
sodium channels or reducing vesicular glutamate transporter expression they 
stabilise membranes and control release of glutamate (lamotrigine, valproate, 
topiramate). These drugs favour glutamate uptake via excitatory amino acid 
transporters (EAAT) EAAT1 and EAAT2 to neighbouring astrocytes (valproate). 
Blockade of glutamate kainate/AMPA receptors (perampanel, topiramate) and the 
alteration of subunits expression, phosphorylation and trafficking will ultimately 
affect receptor function (lithium, valproate, lamotrigine). In addition to their well-
established effects on GABA function (topiramate and valproate) (Macdonald and 
Kelly, 1995; Ueda and Willmore, 2000), it seems that the rebalancing between 
excitatory and inhibitory transmission is involved in mediating the therapeutic 
benefits of these drugs. 
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Table 3. The targets of selected drugs with respect to glutamatergic transmission (modified from Sanacora et 
al., 2008).
Drug Effect References
Lithium Increases VGLUT1 expression and presynaptic
glutamate release
Moutsimilli et al., 2005; Dixon et al., 
1994; Hokin et al., 1996
Acutely inhibits, chronically upregulates glutamate uptake Dixon and Hokin, 1998
Reduces the level of GluN2A and GluN2B subunit 
phosphorylation; Decreases Src and Fyn interactions 
with GluN2A subunit mediated by PSD-95
Reduces the level of GluA1 and GluA2 subunits in 
synapses and attenuates phosphorylation of GluA1 at 
its PKA site S845; reduces AMPA/NMDA ratio
Hashimoto et al., 2002; Basselin et
al., 2006; Ma and Zhang, 2003
Du et al., 2008; Du et al., 2003; Du 
et al., 2004
Valproate Reduces VGLUT1 and glutamate release Cunningham et al., 2003; Kang et 
al., 2005
Increases levels of glutamate transporters EAAT and 
astrocytic uptake
Hassel et al., 2001; Ueda and 
Willmore, 2000
Inhibits AMPA binding
Reduces the level of GluA1 and GluA2 subunits in 
synapses and attenuates phosphorylation of GluA1 at 
its PKA site S845;
Blocks NMDA receptors
Kunig et al., 1998
Du et al., 2008; Du et al., 2003; Du 
et al., 2004; Du et al., 2007
Ko et al., 1997; Steppuhn and 
Turski, 1993; Zeise et al., 1991
Lamotrigine Blocks voltage-gated sodium channels Leach et al., 1991; Zona and Avoli, 
1997
Reduces glutamate release Ahmad et al., 2005
Inhibits AMPA receptor
Increases the level of GluA1 and GluA2 subunits in 
synapses and enhance phosphorylation of GluA1 at 
its PKA site S845;
Lee et al., 2008
Du et al., 2007
Topiramate Blocks voltage-gated sodium channels Gibbs et al., 2000; Wu et al., 1998;
Zona et al., 1997
Blocks glutamate kainate/AMPA receptors Angehagen et al., 2003; Shank et 
al., 2000
Perampanel Blocks AMPA receptors Rogawski and Hanada, 2013
Abbreviations: vesicular glutamate transporter 1 (VGLUT1), Src and Fyn (two members of the Src family of protein tyrosine 
kinases), post-synaptic density protein (PSD-95), PKA (protein kinase A), EAAT, excitatory amino-acid transporter.
2.5 BIPOLAR DISORDER, SCHIZOPHRENIA AND SCHIZOAFFECTIVE 
DISORDER
Bipolar disorder is characterised by cycles of mood swings, from episodes of 
mania (bipolar type I) or hypomania (bipolar type II) to depression (Table 4). The 
manic episode consists of long periods of feeling ‘high’ and excessively elevated, 
expansive or easily irritable mood (Diagnostic and statistical manual of mental 
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disorders 5th ed.; DSM-V; American Psychiatric Association, 2013). Other 
behavioural characteristics include inflated self-esteem or grandiosity (an 
unrealistic sense of one's capabilities), significantly decreased need for sleep, 
loquacity or pressured speech, excessive involvement in multiple projects and 
activities and highly risky pursuit of pleasurable activities (for example, activities 
involving drugs, alcohol, or sex). The manic episode of BPD can also include 
psychotic and cognitive symptoms (racing, disconnected thoughts, the flight of 
ideas, distractibility). SCZ is a life-long and debilitating psychotic illness, which 
exhibits both positive symptoms, such as hallucinations, delusions and racing 
thoughts, as well as negative symptoms (affective flattening, avolition, social 
withdrawal) and cognitive deficits (Table 4). A third category - SAD was first 
introduced in DSM–III (1980) (3rd ed.), including the cases with mood episodes in 
addition to psychotic symptoms. In the next manual, DSM–III–R (1987) (3rd ed., 
revised), four diagnostic criteria and two subtypes (bipolar and depressive) of SAD 
were introduced. In the DSM-IV (1994) (4th ed.) and DSM-IV-TR (2000) (4th ed., 
text rev.) mixed episodes within the bipolar type category were added. From that 
time, SAD has remained as a controversial category with constant efforts being 
made to improve the diagnostic criteria in order to differentiate it from SCZ and 
mood disorders and thereby to increase diagnostic reliability (Malaspina et al., 
2013). In an attempt to resolve this discrepancy, in the newest edition (DSM-V) the 
more stringent criteria were defined with regard to the duration of the mood 
episode in the total course of the illness (Table 4).
Nonetheless it is still often difficult to distinguishing SAD from SCZ and from 
mood disorder with psychotic symptoms. In addition, affective symptoms can be 
identified within SCZ and psychotic symptoms can occur in conjunction with mood 
disorders. Thus, both psychosis and mood disturbance may constitute core 
symptoms of BPD, SCZ, and SAD and, in fact, many clinicians support the 
concept that there is a continuum with little or no rigid boundaries between these
entities (Bellivier et al., 2013; Lake and Hurwitz, 2007; Malhi et al., 2008). This is 
evidenced by overlapping pathophysiological mechanisms of psychotic and 
affective disorders emerging from neurochemical, neuroimaging, 
neurodevelopmental, psychopharmacological, epidemiological and genetic studies 
(Altshuler et al., 1998; Arnone et al., 2009; Baumann and Bogerts, 1999; Berrettini, 
2004; Blumberg et al., 2003; Brambilla et al., 2001; Craddock et al., 2006; Fornito 
et al., 2009; Strakowski et al., 1999; Walker et al., 2002; Wright et al., 2000). For 
this reason, the term schizoaffective will be used throughout this manuscript, as an 
umbrella term to describe both schizophrenia-like symptoms and affective 
symptoms. Furthermore, the term psychotic disorders will be used to emphasize 
the key phenotypic similarities.
Major endeavours have been undertaken to identify affected genes, being 
largely conducted by microarray analysis in post-mortem brains of patients. The
confounding effects of medications and the inability to detect markers during a
specific state (e.g. during a manic episode) complicate interpretation of the results,
but nevertheless, these studies have revealed several genes apparently implicated
in pathology of SCZ and BPD (Lin et al., 2012). The majority of genes code for
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proteins involved in synaptic signalling and neuronal and glial functions but also in 
cellular metabolic processes. The most consistently reported genes have been 
those ????????????-aminobutyric acid (GABA) and glutamatergic neurotransmission,
e.g. the expressions of alpha 5 GABA receptor (coded by GABRA5 gene) and 
mGluR3 metabotropic glutamate receptor (coded by GRM3 gene) have been 
claimed to be increased in the prefrontal and the anterior cingulate cortex in BPD 
(Choudary et al., 2005) whereas their expression appears to be downregulated in 
the prefrontal cortex (PFC) and the entorhinal cortex in SCZ (Duncan et al., 2010; 
Hemby et al., 2002). Furthermore, the expression of glutamate decarboxylase-1
has been consistently reported as being downregulated in both SCZ and BPD 
(Duncan et al., 2010; Hashimoto et al., 2008; Vawter et al., 2002). The candidate-
gene based population and family association studies have also hinted at the 
involvement of some ionotropic glutamate receptor genes (GRIN1, GRIN2A, 
Table 4.  Highlights of diagnostic criteria for bipolar mania, schizophrenia and schizoaffective disorder 
according to DSM-V.
Bipolar disorder Schizophrenia Schizoaffective disorder
Manic (Bipolar I)/hypomanic (Bipolar II) episode:
A. Abnormally and persistently elevated and 
irritable mood lasting for at least 1 week 
(mania) or 4 days (hypomania)
B. Three (or more) of the following symptoms:
- increased goal-directed activity or energy
- elevated self-esteem or grandiosity
- be more talkative than usual
- have flight of ideas
- a reduced need for sleep
- be easily distracted
- psychomotor agitation
- excessive involvement in activities with 
potential painful consequences
C. Mood disturbance cause marked impairment 
in social and occupational functioning 
(for Bipolar I)
Depression episode:
A. Five (or more) symptoms for at least 2 weeks: 
- depressed mood
- diminished interest
- insomnia or hypersomnia 
- fatigue or loss of energy
- feeling of worthlessness or guilt
- diminished ability to think or concentrate
B. Marked impairment in social and occupational 
functioning
A. Two (or more) of the 
following, each present 
for a significant portion 
of time during a 1-
month period:
- hallucinations
- delusions
- disorganized speech
- grossly disorganized 
or catatonic behavior
- negative symptoms 
(diminished emotional   
expression or 
avolition) 
B. For a significant portion 
of the time major areas 
of functioning, such as 
work, interpersonal 
relations, or self-care, 
are markedly below the 
level achieved prior to 
the onset.
C. Continuous signs of the 
disturbance persist for 
at least 6 months (this 
include at least 1 month 
of symptoms)
A. An uninterrupted period of 
illness with a major mood 
episode (major depressive or 
manic) concurrent with criteria A 
for schizophrenia. The major 
depressive episode must include 
depressed mood.
B. Delusions or hallucinations for 2 
or more weeks in the absence of 
a major mood episode during the 
lifetime duration of the illness
Note: this criterion 
distinguishes SAD from bipolar 
disorder with psychotic features.
C. Symptoms that meet criteria for 
a major mood episode are 
present for the majority of the 
total duration of the active and 
residual portions of the illness
Note: this criterion 
distinguishes SAD from   
schizophrenia.
Bipolar type: if a manic episode 
is present (major depressive 
episodes may also occur)
Depressive type: if only major 
depressive episodes are part of 
the presentation.
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GRIN2B and GRIK3), metabotropic glutamate receptor genes (such as GRM3) 
and GABA genes (e.g. GAD1 and GABRB2) in both illnesses (Cherlyn et al., 
2010).
Rather than individual neurotransmitter implications in etiology, current 
research is focusing on cellular plasticity cascades that could explain dysfunctions 
in the circuit and behavioural levels that lead to profound motor, cognitive and 
affective deficits (Schloesser et al., 2008). In fact, the standard and still most 
widely prescribed mood-stabiliser medications seem to exert convergent effects on 
signalling pathways that in turn regulate the major neurotransmitter systems and 
thus affecting, preferably stabilising the mood. Those signalling pathways include
protein kinase C (PKC) and myristoylated alanine-rich C kinase substrate,
glycogen synthase kinase-3 (GSK-3), cAMP response element-binding protein and 
brain-derived neurotrophic factor, extracellular receptor coupled kinase and the 
Bcl-2 family of proteins (Schloesser et al., 2008). However, these complex 
phenotypes are greatly influenced by multiple genes that together with 
environmental experiences define individual disease susceptibility (Ginsberg et al., 
2012).
2.6 HISTORY AND CURRENT PHARMACOTHERAPY OF BIPOLAR 
DISORDER, SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
In the late 19th century, the first prophylactic effects of lithium in the treatment of 
recurrent symptoms of mania and depression (Lenox and Watson, 1994) were 
observed. The clinical use of lithium in psychiatry was later disputed but it was 
rediscovered in 1949 when John Cade, the psychiatrist, used lithium to solubilise 
uric acid while studying its role in mania; he reported that animals became 
tranquilised. Lithium efficacy has subsequently been confirmed in many clinical 
trials and for decades it remained standard therapy in BPD. Since it is a small ion, 
lithium can penetrate into neurons through voltage gated sodium channels and it is 
thought to interact with many different intracellular compounds. Even though its
precise targets are still being debated, inositol phosphatases and GSK-3 are two 
putative candidates (Ryves and Harwood, 2001). By inhibiting GSK-3, lithium can 
affect insulin and Wnt signaling and exert effects on metabolism as well as on 
developmental and neuronal processes (Gurvich and Klein, 2002). The depletion 
of the phosphoinositide precursor inositol and blockade of phospholipase-
dependent signalling are induced by another mood-stabiliser, valproate, although it 
is believed that primarily its antiepileptic effects are due to blockade of sodium 
channels. Those two drugs are the first line treatment for BPD, but they are also 
used for treating SCZ and SA disorder. The second-generation antipsychotics 
including olanzapine, quetiapine, risperidone, aripiprazole and the third-generation 
drug, asenapine, are used as adjuncts to mood-stabilisers. Two anticonvulsant
drugs, lamotrigine and topiramate are newer approved treatments being utilized
mainly during the maintenance phase of the illness (Dursun and Deakin, 2001).
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The treatment of SCZ changed dramatically in the mid-1950s with the 
introduction of the first antipsychotic agent, chlorpromazine, which was initially
developed as an antihistaminic (Ban, 2007). As a result, a plethora of agents were 
subsequently synthesized. All of these agents antagonise the DA D2 receptor 
subtype in the mesolimbic dopaminergic system, which has been proven to be 
essential for the alleviation of positive symptoms, hallucinations and delusions
(Howes and Kapur, 2009). However, their use is associated with severe side 
effects such as the extrapyramidal syndrome and hyperprolactinaemia due to 
blockade of other DA pathways, the nigrostriatal and tuberoinfundibular,
respectively. The safety profile was partly improved with the appearance of the 
second-generation antipsychotics that simultaneously blocked both D2 DAergic 
and 5-HT2A serotonergic (5-HT) receptors, possibly with higher affinity for the 
latter receptors (Meltzer, 1996). The blockade of 5-HT2A receptors is thought to
release the dopaminergic cells in the nigrostriatal DA pathway from 5-HT-induced
inhibition and the resulting increase in DA release may reduce the extrapyramidal 
syndrome. Others have proposed that a drug with low affinity for D2 DA receptors 
and faster dissociation could possess better therapeutic efficacy with a lower risk 
of side-effects (Kapur and Seeman, 2001). These so-called “atypical 
antipsychotics”, along with their typical counterparts, have different binding 
affinities towards ???????????????????????????????????????????-adrenergic receptors, 
H1-histaminergic receptors, muscarinic receptors and many of the 5-HT receptor 
subtypes, which contributes to their many other side-effects (Miyamoto et al., 
2012; Pratt et al., 2012). However, atypical antypsychotics lack efficacy to combat 
the cognitive and negative symptoms of schizophrenia and the treatment of these 
symptoms still remains a largely unmet clinical need (Pratt et al., 2012).
Aripiprazole, referred to as a third-generation antipsychotic agent, in that sense is 
specific as it is a partial agonist of the D2 receptor. Not only does it reduce the 
hyperactive mesolimbic dopaminergic pathway, but it also activates the hypoactive 
mesocortical dopaminergic pathway, which it thought to be associated with 
negative symptoms and cognitive impairment. Aripriprazole also acts as an 
antagonist of 5-HT2A receptors and a partial agonist of 5HT1A receptors. It has 
been associated with less weight gain and fewer metabolic side effects than the 
older generation drugs (Swainston Harrison and Perry, 2004).
There are few controlled clinical studies which support the use of antipsychotic 
drugs and mood-stabilisers for the treatment of patients with SAD, depending on 
the specific subtype of the SAD (Levinson et al., 1999).
2.7 STRATEGIES IN THE DEVELOPMENT OF NOVEL DRUGS
The current pharmacotherapy of psychotic disorders is reliant on the drugs first 
discovered decades ago. Although their targets are being re-examined and novel 
mechanisms revealed, the plight of patients who are treatment resistant remains 
unanswered. Nonetheless, the future of drug development must be based on 
developing comprehensive, relevant and informative animal models. 
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The variable response to antipsychotics, the suboptimal treatment of negative 
and cognitive symptoms and the possibility of serious side effects, as well as the 
failure of disturbed monoamine signalling hypothesis to explain phenotypic 
complexity have all contributed to a shift of drug targeting towards modulation of 
major excitatory and inhibitory transmission (Coyle and Duman, 2003). The 
evidence that the dopaminergic disturbances are in fact preceded by glutamatergic 
dysregulation was the stimulus to evaluate the therapeutic properties of a variety 
of compounds that modulate the function of glutamatergic synapse. The potential 
targets for drug development are shown in Fig. 3. Modulation of presynaptic 
vesicular loading of glutamate, modulation of presynaptic vesicular glutamate 
release, voltage-dependent Na+ channel modulation that regulates glutamate 
release, modulation of extrasynaptic glutamate release, modulation of group I 
mGluR, post-synaptic density proteins, AMPA receptor modulation, 
synaptic/extrasynaptic NMDA receptor modulation, facilitation of glutamate 
clearance by EAATs and modulation of group II mGluR can all potentially be 
exploited (see Fig. 3).
Administration of glycine, the glutamate co-agonist at NMDA receptors, is one 
approach which can be used to boost the NMDA function on GABAergic 
interneurons (Noetzel et al., 2012; Tsai and Lin, 2010). In order to circumvent the 
poor pharmacokinetics of glycine, many drug companies have tried to develop 
glycine transporter inhibitors (sarcosine, bitopertin) that would elevate the 
concentration of glycine in synapse (Lane et al., 2005; Lane et al., 2006). Another 
approach which can be applied to regulate NMDA receptor function is to target
group V metabotropic glutamate receptors that both physically (via binding to 
scaffolding proteins Homer and Shank) and functionally interact with ionotropic 
receptor (Ehlers, 1999). These kinds of positive allosteric modulators of mGluR5 
receptors would display more specific binding and thus potentiate NMDA 
responses (Kinney et al., 2005). Many of these agents have progressed to clinical 
trials, but problems with in vivo safety and propensity to induce convulsions have 
limited exploitation of their therapeutic potential (Rook et al., 2013). Alternatively, 
drugs with preferential effects at alpha-2 subunit-containing GABA receptors would 
enhance GABAergic tone on glutamatergic projection neurons and decrease the 
downstream effects of glutamate receptor activation (Lewis et al., 2005). In 
addition, agonists at group II of mGluR, mGluR2/3 agonists, proved useful in 
preclinical models predictive of antipsychotic activity, by removing excessive levels 
of glutamate in PFC, thought to underlie some of positive schizophrenic symptoms
(Schoepp and Marek, 2002; Fell et al., 2012).
Minocycline, a tetracycline-type antibiotic, unexpectedly exerted both 
neuroprotective and anti-inflammatory effects counteracting the activation of 
microglia and neuroinflammatory process involved in mood disorders (Hewlett and 
Corbett, 2006; Molina-Hernandez et al., 2008; Tikka and Koistinaho, 2001).
Minocycline was able to block the actions of an NMDA antagonist in rats (Zhang et 
al., 2007) and it could reverse PCP-induced cognitive deficits (Fujita et al., 2008).
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Figure 3. The glutamatergic synapse and targets for drug development: modulation of presynaptic 
vesicular loading of Glu (a); modulation of presynaptic vesicular Glu release (b); voltage-dependent sodium
channel modulation that regulates Glu release (c); modulation of extrasynaptic Glu release (d); Group I mGluR 
modulation (e); post-synaptic density proteins (f); AMPA receptor modulation (g); synaptic NMDA receptor 
modulation (h); extrasynaptic NMDA receptor modulation (i); facilitation of Glu clearance by EAATs (j); Group 
II mGluR modulation (k). Gln (glutamine), Glu (glutamate), VGLUTs (vesicular Glu transporters), SNARE (N?
ethylmaleimide-sensitive factor attachment receptor proteins), EAATs (excitatory amino-acid transporters). 
Modified from Sanacora et al., 2008.
Several other neuromodulators have emerged that target estrogen receptor or 
cannabinoid system (Roser et al., 2010; Zuardi et al., 1991). Oestrogen displayed 
some neuroprotective effects in vitro and in vivo and efficacy in neurological and 
neurodegenerative disease. The interest in the cannabinoids originates from the 
findings of increased incidence of SCZ with cannabis smoking (Moore et al., 
2007). Cannabidiol may also modulate glutamatergic transmission, as it has been 
shown to inhibit ketamine and MK-801-induced effects in animals (Long et al., 
2006; Moreira and Guimaraes, 2005).
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Since there is some data indicating that there are elevated cortical glutamate 
levels specifically in the early phases of the illness (Theberge et al., 2003) and in 
the prodrome (Stone et al., 2009), it has been speculated that drugs that could 
reduce cortical glutamate release (such as mGluR2/3 agonists), or inhibit its 
effects (such as AMPA antagonists and possibly minocycline) could represent be 
disease-modifying agents if administered early enough in the course of disease 
progression (Stone, 2011).
2.8 ANIMAL MODELS OF SCHIZOAFFECTIVE PHENOTYPE
An ideal animal model of disease should fulfil three validity criteria – (1) to have 
symptoms (face validity), (2) to display a common etiology with human disease
(construct validity) and (3) to respond to current pharmacotherapeutic agents and 
procedures (predictive validity).
Face validity means that the model has to recapitulate important anatomical, 
biochemical, neuropathological or behavioural features of a human disease. It is 
very unlikely that any animal model of a neuropsychiatric disorder would 
recapitulate human disease with respect to its complex symptomatology. 
Therefore, the validation of separate tests for separate symptoms of the disease 
that together form a comprehensive battery is commonly utilized (Gould and Einat, 
2007).
In the past, most of models of schizoaffective phenotype focused on
hyperactivity as a dominant positive symptom, and although these appeared to be
useful in predicting efficacy of therapeutics (predictive validity), current research 
has taken endophenotype (intermediate phenotype) approach. This entails 
attempting to identify any biochemical, anatomical or endocrine markers, heritable 
and state independent (Gould and Gottesman, 2006), in order to increase 
construct validity linking the model to human pathophysiology. However, the 
etiologies of BPD, SCZ and SAD are still unclear.
In general, these animal models are mostly classified into four main categories: 
pharmacological, environmental, nutritional and genetic models (Kato et al., 2007).
While stimulant-induced models of hyperactivity have been traditionally exploited 
for estimating drug efficacy, they largely lack etiological relevance. In addition, the 
current belief is that the effect of nutritional and environmental factors also 
combines with genetic factors in determining disease susceptibility. Nonetheless, 
the detected susceptibility genes from gene-expression profiles obtained from 
patient cells and tissues, despite their limitations, provide valuable data that are 
used in turn to produce rodent models with manipulated genes. Such reverse 
translation strategies are useful ways to circumvent the problem of the functionality 
at the brain-circuitry level (Lin et al., 2012) and these genetic models possess 
greater construct validity.
Antagonism of NMDA receptors with MK-801, PCP and sub-anaesthetic dose 
of ketamine produce locomotor hyperactivity in rodents and promote or exacerbate 
SCZ-like symptoms in humans. The NMDA antagonists induce the efflux of 
31
glutamate in the prefrontal cortex, where it acts on non-NMDA receptors further 
eliciting dopamine release (Moghaddam and Adams, 1998). The effects can be 
abolished by administration of an antagonist of the AMPA/kainate receptor. 
Furthermore, the behavioural hyperactivity after blockade of NMDA receptors can 
be attenuated by lithium and valproate, and by group II mGluR agonist (Ghedim et 
al., 2012; Moghaddam and Adams, 1998). This model represents a well-accepted 
and widely used rodent model of psychosis and it reconciles, at least partly, all of 
the validity criteria. Moreover, it places the dopaminergic system in a secondary
position to the glutamatergic system but it also confirms the close interaction 
between these two transmitters. Recently, several glutamatergic models have 
been exploited, shifting the focus of research away from dopaminergic system. 
Complete animal behavioural correlates of human behaviour are unattainable, 
but hyperactivity, social behaviour, cognitive deficits, aggressive behaviour, risk-
taking, anxiety-like and depression-like behaviours are commonly used to test for 
schizoaffective symptoms. Table 5 summarises genetic glutamatergic mouse 
models and lists the face and predictive validity for the aforementioned symptoms.
Mouse models with targeted mutagenesis of glutamate receptors or proteins 
interacting with glutamate receptors that indirectly affect the receptor function are 
presented. These genetic models also make it possible to study the genes that 
regulate brain development and which are involved in pathogenesis of psychotic 
disorders. Due to the global deletion of these genes, the compensatory 
mechanisms might hamper the interpretation of the adult phenotype. It has been 
speculated that to overcome these disadvantages, time- or region-specific gene 
manipulation would permit better control over gene function in the examining the 
onset of disease or symptom manifestation (Havekes and Abel, 2009).
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Table 5. Highlights of glutamatergic genetic rodent models of schizoaffective symptomatology.
Model Behavioural symptoms Predictive validity 
(reversal of symptom 
by drug)
Reference
Mice with mutations affecting ionotropic glutamate receptors
Grin1hypo,
with reduced expression of 
NMDA GluN1 subunit 
Hyperactivity
Stereotypy
Cognitive deficits
Social interaction deficits 
Deficit in pre-pulse inhibition
Haloperidol 
Clozapine
Barkus et al., 2012a;
Duncan et al., 2006;
Mohn et al., 1999
????????????
deficient in NMDA receptor 
GluN2A subunit
Hyperactivity
Cognitive deficits 
Social interaction deficits
Less despair-like behaviour
Low anxiety
Haloperidol 
Risperidone 
Boyce-Rustay and 
Holmes, 2006;
Miyamoto et al., 2001
?????????,
deficient in kainate receptor 
GluK2 subunit
Hyperactivity
Risk-taking behaviour 
Aggressive behaviour
Less despair-like behaviour
Enhanced locomotion to
psychostimulant
Lithium 
Lithium 
Lithium 
Shaltiel et al., 2008
?????????,
deficient in delta receptor 
GluD1 subunit
Hyperactivity
Low anxiety
Despair-like behaviour
Aggressive behaviour 
Social interaction deficits
Lithium 
D-Cycloserine
Yadav et al., 2012
Mice with mutations in proteins associated with glutamate receptors
Shank3 overexpressing 
transgenic mice
Hyperactivity (in home cage)
Deficit in pre-pulse inhibition
Enhanced locomotion to
psychostimulant
Less despair-like behaviour
Valproate
Valproate
Valproate
Guilmatre et al., 
2014; Han et al., 
2013
2.9 GLUA1 SUBUNIT-DEFICIENT MOUSE LINE (GRIA???? MICE)
Since there are no relevant subunit-selective pharmacological agents for AMPA 
receptors, the gene targeting approach has provided novel insights into the role of 
individual subunits. A mouse line deficient in gria1 gene (equals GRIA1 in human 
genome) was generated in 1999 (Zamanillo et al., 1999) and it is available at the 
Jackson Laboratory (B6N.129-Gria1tm2Rsp/J, stock number: 019012). From that 
time, extensive research on ???????? mice aimed at elucidating the role of the 
GluA1 subunit-containing AMPA receptor in learning and memory, addiction and 
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neuropsychiatric diseases, conditions where perturbed glutamatergic signalling 
has been suspected.
2.9.1 THE BEHAVIOURAL PHENOTYPE
The basic characteristics of ???????? mice do not differ from the Gria1+/+ wild-
type line (WT); i.e. their physical health, body weight, food consumption, 
nociception, neurological, motor, sexual, sensory functions and circadian rhythm 
seems to be normal (Bannerman et al., 2004; Chourbaji et al., 2008; Feyder et al., 
2007; Fitzgerald et al., 2010; Hartmann et al., 2004; Procaccini et al., 2011;
Vekovischeva et al., 2004; Vekovischeva et al., 2001).
The extensive behavioural characterization hinted at anti-anxiety, 
schizophrenia-like and depressive-like phenotype. In tests for anxiety-like 
behaviour (elevated plus maze, dark-light box), the behaviour of ???????? mice 
seemed to be inconsistently altered: from somewhat less anxious (Fitzgerald et al., 
2010; Vekovischeva et al., 2004), through normal (Mead et al., 2006) even to more 
anxious than WTs (Bannerman et al., 2004). A deficiency in pre-pulse inhibition 
(PPI) of acoustic startle is thought to be indicative of psychosis-related properties 
(Wiedholz et al., 2008). The increased learned helplessness pointed to the 
presence of deficits in coping abilities in aversive situations and depressive 
phenotype of ???????? mice (Chourbaji et al., 2008).
Furthermore, the spatial working memory of ???????? mice was reported to be
disrupted (Reisel et al., 2002; Sanderson et al., 2009). Despite the prominent role 
the GluA1 has in adaptive processes underlying learning and memory, cognitive 
tests revealed no impairment in spatial reference memory (Zamanillo et al., 1999;
Sanderson et al., 2009). In contrast, a cellular correlate for learning and memory, 
long-term potentiation (LTP), was lacking in Schaffer collateral - CA1 pyramidal 
cells of ???????? mice, where it is believed that insertion of AMPA receptors and 
modifications in the GluA1 subunit are essential. Consequently, the direct linking 
of these two phenomena became questionable. Subsequently, spared GluA1-
independent LTP of ???????? mice was demonstrated using a different induction 
protocol (Hoffman et al., 2002; Jensen et al., 2003; Romberg et al., 2009). The 
LTP depended on GluN2B-containing NMDA receptors, neuronal nitric oxide 
synthase and PKC. Thus it is possible that this machinery might regulate the 
activity-dependent, synaptic expression of AMPA receptor by interacting with the 
GluA2 subunit. 
As drug addiction is often described as maladaptive learning, the mouse line 
has been extensively utilized in studying addiction-related phenomena (Allison and 
Pratt, 2003; Luscher and Malenka, 2011). The development of tolerance after 
chronic administration of benzodiazepines and morphine is thought to involve the
GluA1 subunit and it is deficient in ???????? mice (Aitta-Aho et al., 2009;
Vekovischeva et al., 2001). There is a report that the mechanism mediating 
withdrawal might be different in these two classes of drugs as the withdrawal after 
benzodiazepines was enhanced whereas that encountered after morphine was 
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reduced. Sensitisation to morphine was retained in ???????? mice only in the 
presence of environmental cues (Vekovischeva et al., 2001). There is a report that 
opioid-induced glutamate receptor neuroplasticity is impaired in ???????? mice as 
the morphine induced state-dependency was absent (Aitta-Aho et al., 2012).
???????? mice exhibited remarkably reduced aggression, lacking the ability to 
adapt to social encounters (Vekovischeva et al., 2004). In support of these data, 
treatment with the AMPA receptor antagonist reduced aggression in mice 
selectively bred for high aggression (Vekovischeva et al., 2007). Thus, it is 
believed that the GluA1 protein is essential for properly directing the behaviour of 
survival significance in the natural habitat.
The most striking and most readily reproducible phenotype of ???????? mice is 
hyperactivity provoked by environment. The locomotor activity of ???????? mice 
was similar to that of WT littermates in the familiar environment of their home cage 
(Wiedholz et al., 2008). However, locomotor activity increased dramatically (at 
least doubling) in an unfamiliar environment of novel cages and this elevation was 
sustained for up to 4-h (Bannerman et al., 2004; Chourbaji et al., 2008; Fitzgerald 
et al., 2010; Procaccini et al., 2011; Vekovischeva et al., 2001). In the WT mice,
repeated exposure to novel cages evoked habituation, demonstrable as a
diminished response, but in ???????? mice this phenomenon was lacking. There is 
a report that any confrontation with a novel signal, such as a new object or 
littermate confrontation, may cause an aberrant reaction in ???????? mice 
(Wiedholz et al., 2008).
2.9.2 THE NEUROCHEMICAL PHENOTYPE
Subsequently, other studies evaluated the neurochemical changes of ????????
mice and found unaltered 5-HT and noradrenaline contents in various brain 
regions, including hippocampus (Vekovischeva et al., 2004). However, another 
study reported decreased hippocampal 5-HT and noradrenaline that were linked to 
the depressive-like phenotype (Chourbaji et al., 2008). The discrepancies in the 
results might be related to the different manipulations deployed, i.e. in the first 
experiment, the effects were analysed after a short period of social isolation but in 
the latter in the baseline state. Moreover, no apparent changes in dopamine 
transporter expression, affinity for dopamine and dopamine release appeared in 
striatum, but nonetheless this, dopamine clearance was slightly decreased 
(Wiedholz et al., 2008). The hyperactive phenotype of ???????? mice could not be 
rescued simply by depletion of the dopamine level however, but it could be 
reversed partly by haloperidol, leading to the proposal that regulation of this 
behaviour is beyond dopaminergic transmission itself (Fitzgerald et al., 2010;
Wiedholz et al., 2008). Indeed, in the ???????? mouse line increased total 
glutamate levels have been described (Chourbaji et al., 2008), which might drive 
the dopaminergic system hyperactivity. The plasma corticosterone levels and 
hippocampal glucocorticoid receptor expression of ???????? mice appeared to be
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normal in acute stress episode, evidence for a non-altered stress-induced 
response in the ???????? mice (Fitzgerald et al., 2010; Fumagalli et al., 2011).
The life-long deletion of gria1 gene would be expected to trigger some 
compensatory changes, particularly when one of the key regulators of neuronal 
plasticity is missing. In fact, in the genome expression profiling study in 
hippocampal tissue, 38 genes were found to be altered by more than 30%, with 
the major part of those affected apparently being calcium handling genes. This is 
probably due to low calcium influx as the amounts of all GluA1 partnering Ca2+-
permeable channels were reduced. In turn this might have affected (caused
elevation) one of the major regulators of Ca2+ inflow through the cell membrane, 
i.e. the GluN1 subunit protein level of NMDA receptors, as seen in hippocampus 
(Chourbaji et al., 2008; Zhou et al., 2009). The normal functionality of NMDA 
receptors (Vekovischeva et al., 2004; Vekovischeva et al., 2001) appeared to be 
compromised to some extent in the kind of situations that require behavioural 
plasticity, e.g. in stressful situations, when the serine-phosphorylation of GluN1 
and GluN2B of NMDA receptor subunits was lacking (Fumagalli et al., 2011).
The activity-related changes of ???????? neurons have been monitored with 
the immediate early genes (IEGs). The lack of GluA1 evoked the up-regulation of 
activity-regulated cytoskeletal associated protein and c-Fos in hippocampus 
(Fumagalli et al., 2011; Procaccini et al., 2011), in a modestly-stressful situation 
such as immobilisation or a change in the animal’s environment. In contrast, the 
induction of IEGs after electroconvulsive shock remains similar between two 
genotypes (Zamanillo et al., 1999).
No changes were observed in synaptic transmission in ???????? mice, 
however, there were extensive reductions of AMPA current in the soma of CA1 
pyramidal cells in ???????? mice (Zamanillo et al., 1999). This means that the 
deletion of GluA1 subunit had particularly affected extrasynaptic receptors, with 
the remaining GluA2/A3 and GluA3/A4 subunits being targeted to synapse. At the 
subcellular level, there was a re-distribution rather than any up-regulation of GluA2 
subunit: it remained in the soma since there was a lack of suitable partner to 
achieve synaptic delivery (Mead and Stephens, 2003; Zamanillo et al., 1999). On 
the other hand, another study found that the levels of GluA2 and GluA4 were 
slightly reduced, perhaps due to a shorter half-life in the unassembled form 
(Jensen et al., 2003). Indeed, the functionality of remaining AMPA receptors 
seemed to be compromised as AMPA binding was markedly lower than the level 
in the WT (Vekovischeva et al., 2004). Interestingly, there were changes in the 
excitatory synapse to VTA DA neurons in ?????????mice with an increase of basal 
AMPA/NMDA receptor current ratio being observed (Aitta-Aho et al., 2012; Dong 
et al., 2004), probably involving some compensatory mechanisms.
2.9.3 PHARMACOLOGICAL CHARACTERISATION 
Despite being proposed as exhibiting a schizoaffective phenotype, ????????
mice have been insufficiently characterised pharmacologically. The drugs
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examined have mostly targeted monoaminergic or glutamatergic transmission and 
involved both acute and chronic studies. The DA D2-like receptor antagonist and 
neuroleptic agent, haloperidol, reduced the locomotor hyperactivity of both 
???????? mice and WT mice (Wiedholz et al., 2008). Since it is a mood-stabiliser, 
lithium partially rescued hyperactivity, but treatment with the inhibitor of GSK-??,
SB216763, was ineffective (Fitzgerald et al., 2010). Ultimately, no effect was seen 
with the positive modulator of the AMPA receptor and there were variable effects 
found with AMPA/kainate antagonists on the characteristic locomotor hyperactivity 
of ???????? mice. Treatment with a noncompetitive antagonist of the AMPA 
receptors, GYKI 52466, was ineffective at attenuating the ????????
hyperlocomotion (Fitzgerald et al., 2010), but it was dose-dependently reduced by 
NBQX (Procaccini et al., 2011). The competitive antagonist, NBQX, might have 
greater selectivity for the AMPA receptor, suggesting that transmission through 
AMPA receptors may be involved in mediating the hyperactive behaviour.
Hyperlocomotion and reduced immobility were insensitive to manipulations of 
serotonergic system (Procaccini et al., 2011), which rather tend to reject the 
depressive-like symptomatology of the ???????? mice as previously postulated
(Chourbaji et al., 2008).
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3. AIMS OF THE STUDY
The GluA1 subunit of the AMPA receptor is known to play an essential role in the 
several adaptive processes of our brain, important for processing of the novel 
signals and crucial for the reward behaviour. In addition, the importance of the 
glutamatergic neurotransmission in the pathophysiology of neuropsychiatric 
diseases has been addressed extensively. Although initially postulated as a 
putative model for schizoaffective symptomatology, ???????? mice have not been 
subjected to an extensive substantial pharmacological characterization. 
The specific aims of this study were:
1. To assess pharmacological treatments targeting glutamatergic 
transmission for reversing the hyperactivity phenotype of ???????? mice in a novel 
environment (I, II, III) and to assess the role of handling on the drug effect on 
hyperactive phenotype of ???????? mice (III).
2. To assess how pharmacological treatments targeting glutamatergic 
transmission could alter the behaviour  of ???????? mice in other tests specific for
schizoaffective symptoms, such as anxiety-like and risk-taking behaviour, despair-
like behaviour, social behaviour, hedonistic behaviour (sucrose drinking, access to 
running wheel) and to characterise impulsive-like behaviour of the ???????? mice
(I).
3. To assess the efficacy of selected pharmacological treatments on novelty-
induced activation of brain regions in ???????? mice and WTs by measuring c-Fos 
expression (II, III).
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4. MATERIALS AND METHODS
4.1 ANIMALS
????????? mice and their Gria1+/+ wild-type controls originating from 
heterozygous breeding, were genotyped after weaning as reported earlier 
(Zamanillo et al., 1999). The ?????????mouse line was backcrossed to C57BL/6J 
for more than 10 generations. During the course of the experiments, they were 
housed individually or in groups of 2-6 of the same-sex in plastic cages (with 
aspen chip beddings and a wooden toy/ shelter and nesting material), under 
standard laboratory conditions (12-h light-dark cycle; lights on at 6:00 a.m.;
temperature 20–23ºC; relative humidity 50–60%). Food pellets and tap water were 
available ad libitum. All tests were performed between 08:00 and 14:00h. The
animal testing procedures were approved by the State Provincial Government of 
Southern Finland (ESAVI-0010026/041003/2010 and ESAVI/2015/04.10.07/2013). 
All efforts were made to minimise the number and suffering of animals. Table 6
shows the total number of animals used in the studies. Male and/or female mice 
were randomly assigned to drug-treatment or control groups. The effect of chronic
treatment with lamotrigine on locomotor activity was performed on females,
whereas the assessment of behaviour in the second battery of tests in the study I 
(I, Fig.1) and in the Intellicage (unpublished data) was performed on males mainly.
The tests were conducted blindly to genotype and/or treatment.
Table 6. Overview of the number of ?????????mice and WT mice used in the studies.
Study Test
WT ????????
Males Females Males Females
I, II
III
Locomotor activity
LI, VAL, TOP, LAM, PER
LY354740
52
49
49
49
42
47
50
55
I EPM, FST 25 21 21 22
I SD (+RW), OF, TST, SI, AMPH 36 6 20 5
II
III
c-FOS expression
LI, VAL, TOP, LAM, PER
LY354740
39
17
38
16
31
16
37
16
unpublished 
data
Intellicage
SD (+RW)
Impulsivity
5
17 2
5
25 3
LI, lithium, VAL, valproate, TOP, topiramate, LAM, lamotrigine, PET, perampanel
EPM, elevated plus maze test; FST, forced swimming test; TST, tail suspension test; SD, sucrose drinking; RW, 
running wheel access; OF, open field test; SI, social interaction test; AMPH, D-amphetamine-induced LA test.
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4.2 DRUG-TREATMENTS
Acute or chronic drug administrations were used (Table 7). For the chronic 
treatments drugs were mixed with the food at the doses aimed to be equivalent to
human therapeutic levels. The doses were based on those described in the
literature or from pilot studies. During the course of chronic studies mice were 
monitored daily for all respective toxicity signs. The body weights of mice were
measured at least two times weekly.
Table 7. Summary of drug-treatments.
Drug 
treatment Duration
Dose/kg of 
chow Administration
Lithium Chronic 2.4 g/kg Per os (in a chow)
Valproate Chronic 10 g/kg Per os (in a chow)
Topiramate Chronic 27 mg/kg Per os (in a chow)
Lamotrigine Chronic 75 mg/kg Per os (in a chow)
Perampanel Chronic 60 mg/kg Per os (in a chow)
LY354740 Acute 15 mg/kg30 mg/kg Intraperitoneal
4.3 BEHAVIOURAL METHODS
We assessed the locomotor activity, anxiety-like and exploratory behaviour,
despair-like behaviour, social behaviour, hedonistic and impulsive-like behaviour. 
Study I utilized two behavioural test batteries to measure sets of specific 
behavioural symptoms. The design of testing allowed a sufficient recovery break 
between the tests and the order was carefully selected to minimize the bias and 
stress of multiple testing (I, Fig. 1).
4.3.1 LOCOMOTOR ACTIVITY IN A NOVEL ENVIRONMENT (I, I I , I I I )
Locomotor activity (LA) in a novel environment was observed in plastic cages 
(40 × 30 × 20 cm) as described (Procaccini et al., 2011). Horizontal movements of 
eight to ten mice, placed in visually isolated cages in a sound-attenuated room at 
light intensity of 175 lx were simultaneously recorded for 2 h and analysed 
automatically using video tracking and EthoVision software. 
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4.3.1.1. HANDLING (II I)
In study III, the locomotor activity was evaluated using two cohorts of mice. All 
mice were naïve to injections in the first cohort. In the second experiment, mice 
were briefly handled and injected with saline intraperitoneally daily for 1 week prior 
to their introduction into novel cages and measurement of LA. This was done for 
the purpose to analyse c-Fos expression to avoid any injection-induced stress and 
its influence on brain c-Fos expression.
4.3.2 ELEVATED PLUS MAZE (I)
The elevated plus maze (EPM) test was selected for the purpose of assessing 
innate mouse anxiety in novel unshielded places. The movements of a mouse 
within the central platform, open and enclosed arms of a maze were recorded for 5 
min and were analysed automatically with the EthoVision software (Linden et al., 
2006).
4.3.3 FORCED SWIMMING AND TAIL SUSPENSION TEST (I)
The forced swimming test (FST) as well as tail suspension test (TST) assess 
an animal’s ability to cope in an inescapable situation by placing it in a transparent 
cylindrical beaker with water or attaching the mouse by the tail to an elevated 
metal bar for 6 min (Flaisher-Grinberg and Einat, 2009). Video-recorded data were 
analysed later by Ethograph software.
4.3.4 VOLUNTARY SUCROSE DRINKING AND RUNNING WHEEL
ACTIVITY (I)
To assess hedonic behaviour, the preference for the sucrose and activity on 
running wheels (RWs) of the ?????????mice and WTs were evaluated (Flaisher-
Grinberg et al., 2009). Mice had daily alternate access to water and sucrose (8% 
weight/volume) for 6 days. For the next 6 days, additional natural rewarding 
stimulus (RW) was introduced, to test for the different interaction of the stimuli on 
the behaviour of ?????????mice and WTs. As the result, the sucrose preference 
was calculated as a percentage of sucrose intake as a part of the total fluid. Wheel 
revolutions indicate running activity on RW. 
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4.3.5 OPEN FIELD TEST WITH NEW OBJECT EXPLORATION (I)
Additionally, in order to evaluate anxiety and explorative activity, the open field 
test was combined with new object exploration (Ramos, 2008). After an initial 3 
min of exploration, a round, textured object was placed in the centre of the open 
field and the mouse was allowed to examine it for the next 3 min. Locomotion in 
different zones was tracked automatically with Ethovision whereas object-related 
behaviours were analysed with Ethograph. 
4.3.6 SOCIAL INTERACTION (I)
Social interaction was evaluated in a new territory with fresh bedding 
(Vekovischeva et al., 2013). The behaviour of two to three animals was video-
recorded and analysed by the Ethograph software. Their behaviour was 
categorized into individual behaviour (without contacts with other members), 
reciprocal (simultaneously-initiated) contacts, and passive contacts (initiated by 
other group members).
4.3.7 RESPONSE TO A PSYCHOSTIMULANT (I)
The locomotor response to a psychostimulant was tested after a single i.p 
injection of amphetamine and analysed by the EthoVision software.
4.3.8 DRINKING BEHAVIOUR AS ASSESSED IN INTELLICAGE
(UNPUBLISHED DATA)
The Intellicage system (2003, NewBehavior Lab, Zürich, Switzerland) is a
computer-based, fully automated testing apparatus, designed to be placed inside a 
large cage (610 × 435 × 215 mm; model 2000P, Tecniplast, Buguggiate, Italy). 
The apparatus is constructed from four operant (drinking) triangular chambers (15 
× 15 × 21 cm), each of them housing only one mouse at a time. Each chamber is 
constructed from an opaque tube (30 mm inner diameter) leading towards two 
drinking bottle nipples, left and right, which are accessible through the 
corresponding drinking windows (13 mm). The access to a bottle nipple is 
regulated by the slide-door that is easily opened by a nose-poke if the door is not 
specifically blocked by the computer-aided algorithm. Intellicage monitors 
individual drinking behaviours based on subcutaneous micro transponders that 
emitted a unique animal code upon entering of drinking chambers: visit(s) into the 
chamber, nose-poke(s) to open the slide-door, and nipple lick to drink. The 
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Intellicage allows comparison of the learning abilities independent of handling or 
introduction to new environment for testing (Galsworthy et al., 2005). The group of 
4-6 mice were housed in the Intellicage under 12-h light/dark cycle (lights on at 8:00 
a.m.) that was equipped with sleeping shelters and food ad libitum.
4.3.8.1 ASSESSMENT OF VOLUNTARY DRINKING BEHAVIOUR OF GRIA????
MICE
Voluntary consumption was monitored under conditions of free access to every 
drinking chamber. The sucrose (200mM) and quinine (1mM) solutions exchanged 
two water bottles and were presented intermittently (every second day) for two 
days. For the following two days, sucrose drinking was analysed when the 
environment was additionally enriched with a running wheel device which the 
animals could use of their own free will.
4.3.8.2 ASSESSMENT OF IMPULSIVE-LIKE BEHAVIOUR OF GRIA???? MICE
We evaluated ability of mice to perform the sequential drinking protocol in a 
clockwise order for 3 days in the presence of water in all chambers (water 
conditions) or when two bottles were exchanged for sucrose and quinine solutions 
(sucrose-quinine conditions) (Fig. 4). In particular, the mice were allowed to drink 
for 5s from the correct chamber (slide-door is opened by a nose-poke), if the 
mouse already drank from the previous one. Thus, the mouse was forced to 
search for a new correct chamber on the next occasion. The violations of the 
protocol as the total number of incorrect visits (Vs) to chambers followed by nose-
pokes (NPs) and the total number of incorrect NPs into the wrong chambers were 
counted for each days (using number of trials for 24-h as a covariate in the 
analysis). Specified mistakes in each of the chambers in the sucrose-quinine 
conditions were calculated as the proportion (%) of the total number of the 
incorrect Vs and incorrect NPs made per 24-h. The number of incorrect NPs that 
the mice made in the out-of-turn chamber reflected impatience of mice to get a 
drink from that particular chamber.
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Figure 4. Experimental schedule of drinking behavior in the Intellicage under water and sucrose-
quinine conditions (SQ). Bolded circles indicate the four drinking chambers (Ch) located in the corners of the 
Intellicage. Arrows indicate the clockwise sequence of the drinking protocol. The trial always started from the 
(Ch0). W1 is a water-containing chamber placed before a sucrose one, and W2 before a quinine chamber 
according to the clockwise order. The mice drinking behaviour in water and sucrose-quinine solutions was
followed simultaneously for 3 days.
4.4 ANALYTICAL AND NEUROCHEMICAL METHODS
4.4.1 DRUG CONCENTRATIONS (I)
The concentrations of lithium and lamotrigine were analysed from the serum 
samples collected after test of LA in a novel environment. Specifically, the 
concentrations of lithium were determined by a colorimetric method in NordLab 
Oulu (Oulu, Finland) and that of lamotrigine by liquid chromatography after solid-
phase extraction in the Rinnekoti-Foundation Laboratory (Espoo, Finland). The 
concentrations of other drugs used in the study could not be determined due to 
methodological problems.
4.4.2 C-FOS IMMUNOHISTOCHEMISTRY (II , I I I)
Following the 2-h novelty-exploration test, the brains of animals were quickly 
dissected, and stored at -80 °C before final cutting on a cryostat for subsequent c-
Fos immunohistochemical detection. Goat anti-c-Fos antibody and biotinylated 
horse anti-goat secondary antibody were used, and the avidin–biotin peroxidase 
complex and diaminobenzidine with nickel sulphate intensification applied for 
visualisation. The resulting detection of c-Fos-positive cells from light-microscope 
captured images was automatic using ImageJ software (II, III), a constant 
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threshold and ‘region of interest’ area. The analysis was blind to the treatment, 
genotype and sex.
4.5 STATISTICAL ANALYSES
Statistical analyses were carried out using IBM SPSS Statistics 21 and GraphPad 
Prism softwares applying two- or three-way Analysis of Variance (ANOVA) or 
Linear Mixed Model (using genotype, drug-treatment and/or sex as factors), with 
repeated measures (days, time-point) and covariate, where applicable. Bonferroni, 
the Least Significance Difference or Newman-Keuls were used as post-hoc tests. 
Pearson’s correlation coefficients were calculated to test the significance of the 
correlations. Paired two-tailed t-test was used to compare the body weights of the 
mice and the differences in expression of c-Fos protein within the group. Statistical 
significance was set at p<0.05.
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5. RESULTS AND DISCUSSION
Table 8 summarises the clinical symptomatology of the psychotic disorders, its 
putative correlates in the ?????????mice in the representative animal tests studied 
here and the response to treatment targeting glutamatergic transmission, if 
assessed. The results of behavioural and pharmacological characterisation of the 
?????????mice will be discussed in the following chapters.
5.1 EFFECTS OF THE DRUG-TREATMENTS ON THE HYPERACTIVITY 
OF THE GRIA???? MICE (I,II,II I)
The most robust and easily-provoked behaviour of ????????? mice is 
hyperactivity, but the mechanism involved in this response has not been clarified 
and this can lead to biased results in other tests. For that reason, the focus of 
these studies was particularly on hyperactivity. It is a shared feature of several 
psychotic disorders, among others manic episode of BPD, SCZ and SAD (DSM-
V). Accordingly, it was decided to probe the responsiveness of this mouse line to 
current pharmacotherapy in order to evaluate the predictive usefulness of the 
model for these disorders. 
Standard mood-stabilisers, lithium and valproate (Fig. 5AB), and the novel 
mood-stabilising anticonvulsants, topiramate and lamotrigine (Fig. 5EF) all 
attenuated the aberrant activity of Gria1???? mice (I). These drugs have been 
documented to possess glutamate-modulating properties and could affect 
components of glutamatergic synapse (Machado-Vieira et al., 2009) (Table 3). 
Hence control of glutamate release or the control of glutamate effects in synaptic 
cleft or at the postsynaptic level could exert substantial antihyperactive effects in 
?????????mice.
Furthermore, we tested the effect of LY354740, a potent and selective 
mGluR2/3 agonist with antipsychotic and antianxiety properties, on hyperactivity of 
????????? mice (III). LY354740 was able to reduce the hyperactivity of male 
?????????mice in naïve (at a dose of 15mg/kg) and pre-handled (at doses of 
15mg/kg and 30 mg/kg) cohorts (Fig. 6AB). Group II mGluRs, mGluR2 and 
mGluR3, are located in presynaptic terminals and negatively modulate glutamate 
excitation by reducing its release (Marek, 2010). The use-dependent activation of 
these receptors provides a form of negative feedback to prevent hyperexcitability 
(Scanziani et al., 1997). In rodents, treatment with an mGluR2/3 agonist has been 
reported to inhibit PCP- and amphetamine-evoked behavioural activation (Fell et 
al., 2008). Since activation of these receptors attenuated the hyperlocomotion, 
their over-reaction to novelty could well stem from enhanced glutamatergic 
neurotransmission, at least in males. Accordingly, Chourbaji et al. reported higher
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Table 8. Face and predictive validity of ?????????mice for symptoms of psychotic disorders. 
Clinical feature
(DSM-V)
Animal test ?????????phenotype 
as compared with 
WTs 
Mood-stabilising effects 
on the ?????????phenotype 
Over-activity
Psychomotor agitation
(chapter 5.1)
Novelty-induced locomotor 
activity
Hyperactivity Attenuation by lithium, 
valproate, topiramate, 
lamotrigine, perampanel and 
LY354740 (I,II,III)
Sensitivity to 
psychostimulants
(chapter  5.1)
Amphetamine-induced 
hyperactivity
Exacerbated 
locomotor phenotype 
No significant effect of drugs
(I)
Risk-seeking/avoidance
Increased/decreased
goal-directed activity
(chapter 5.2.1)
Elevated-plus maze 
Open field test combined with 
new object installation
Increased time spent 
in open arms
Increased interaction 
with the new object
Spent more time on 
the centre of open 
field
Reduction by topiramate (I)
Alleviation after lithium and 
valproate (I)
No significant effect of drugs 
(I)
Resistance to despair
and increased vigour or 
hopelessness
(chapter 5.2.2)
Forced swimming test
Tail suspension test
Increased swimming/ 
struggling
Valproate reduced struggling 
time (I)
Heightened (intense) 
sociability and social 
disinhibition or social 
withdrawal
(chapter 5.2.3)
Social activity in a temporarily 
formed group on new territory
Frequent but short 
reciprocal contacts; 
Dominance of passive 
contacts 
Increased time spent in
social contacts with
valproate (I)
Excessive involvement in 
pleasurable activities and 
seeking for reward or lack 
of pleasure
(chapter 5.2.4)
(chapter 5.2.5.1)
Intermittent presentation of sweet 
solution in the presence/absence 
of running wheels 
Intermittent presentation of sweet 
and bitter solutions in the 
presence/absence of running 
wheels in Intellicage
Increased preference 
for sucrose, but not for
running wheel use
Increased preference 
for sucrose in the 
presence of running 
wheels 
Increased sucrose 
consumption after lithium 
and valproate, but no 
change in running wheel 
activity (I)
Unpublished data (Fig. 7)
Impulsivity
(chapter 5.2.5.2)
Operant drinking sequence 
algorithm in Intellicage, in water 
and sucrose/quinine conditions
Increased impatience 
towards sucrose-
containing chamber
Unpublished data (Fig. 8-9)
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Figure 5. Effects of chronic drug-treatments on hyperactivity of Gria1????mice (I,II). Locomotor 
activities of WT and Gria1???? mice treated chronically with control diet and lithium-, valproate- and 
perampanel-supplemented diets during the first and last 60 min of the exposures to a novel arena (A-D).
Locomotor activities of WT and Gria1???? mice treated chronically with control diet and topiramate- and
lamotrigine-supplemented diets presented during the whole 2-h period (E, F). Data are means ± SEM (n = 5–
27) **p<0.01, ***p<0.001 for the differences between genotypes after the same treatment; #p<0.05, ##p<0.01,
###p<0.001 for the differences from controls of the same genotype; two-way ANOVA followed by Bonferroni 
post-hoc test.
total baseline glutamate levels in hippocampus of ?????????mice (Chourbaji et al., 
2008). Given that mGluR2/3s are also present in heterosynapses, they can 
regulate also the release of other neurotransmitters such as GABA and 
monoamines (Cartmell and Schoepp, 2000). Treatment with perampanel (II) also
attenuated the hyperactivity of the ????????? mice (Fig. 5CD) and this finding 
substantiated the antihyperactive effect displayed after blockade of AMPA 
receptors with NBQX (Procaccini et al., 2011). Perampanel is a novel antiepileptic 
drug and a highly selective antagonist of AMPA receptors over other glutamate 
receptors (Rogawski and Hanada, 2013). These results are consistent with the 
presence of a hyperactive glutamatergic system and are evidence of the role of 
postsynaptic AMPA receptors in mediating behavioural hyperactivity in the 
?????????mice.  
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In fact, treatment with mood-stabilisers achieved an eventual habituation in
?????????mice. Interestingly, the enhanced locomotion of ?????????mice is thought 
to represent deficits in habituation to novel environment, congruent with defective 
short-term memory for spatial stimuli (Sanderson et al., 2009). However, virally-
mediated introduction of GluA1 in the hippocampus of ?????????mice abolished
hyperactivity, but not the working memory deficits (Freudenberg, 2009;
Freudenberg et al., 2013b) complicating direct comparisons between those 
matters. It appears that spatial working memory is only partially dependent on 
GluA1-containing AMPA receptors in hippocampus (Freudenberg et al., 2013b).
It was speculated that in SCZ primarily glutamatergic abnormalities may drive 
the increased responsivity of dopaminergic neurons (Lodge and Grace, 2006;
Stone, 2011). Indeed, glutamatergic projections from the hippocampus increased
dopamine release in the nucleus accumbens which in turn inhibited ventral pallidal 
GABAergic afferents to the VTA and released VTA DA neurons from the inhibition 
(Floresco et al., 2001; Legault et al., 2000; Lodge and Grace, 2006, 2008), with 
subsequently, LA being increased (Sharp et al., 1987; Taepavarapruk et al., 
2000). In ?????????mice, the VTA and striatum seem to have only a minor role in 
mediating the hyperactivity as these structures were not overactivated as 
measured by c-Fos expression in comparison to the situation in WT animals
(Procaccini et al., 2011)(II, Table 1-3). Nonetheless, the baseline AMPA/NMDA 
receptor current ratio was elevated in ????????? mice (Aitta-Aho et al., 2012).
However, despite the elevation of the AMPA/NMDA receptor current ratio in the 
VTA DA neurons of the WT mice 24-h after the administration of diazepam, no 
change was detected in LA (Heikkinen et al., 2009). Similarly, the ablation of the 
GluA1 subunit from dopaminergic neurons does not affect LA (Engblom et al., 
2008).
Amphetamine acutely exacerbated locomotion of ?????????mice, similarly as of
the WT mice (I, see Results). The failure of an amphetamine challenge to alleviate 
the hyperactivity of ?????????mice distinguished this abnormal behaviour from the 
attention deficit hyperactivity disorder-type, where the psychostimulants exert
paradoxical calming effects. The levels of dopamine in various brain regions of 
????????? mice in baseline and the levels evoked by amphetamine were
unexpectedly normal and their striatal clearance of dopamine was only slightly 
reduced (Vekovischeva et al., 2004; Wiedholz et al., 2008). Thus it seems that 
overall, dopaminergic system itself is sensitive to the novelty or stress, but may not 
primarily drive the ?????????mice abnormalities. 
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5.1.1 SEXUAL-DIMORPHISM ON THE ANTI-HYPERACTIVE EFFECTS 
OF LY354740 (II I)
Intriguingly, the effect of LY354740 on attenuating the locomotor hyperactivity was 
restricted to male ?????????mice (Fig.6AB) (III). No previous sexual dimorphism 
has been observed in ?????????mouse line with regards to baseline locomotion, 
response to drugs or distribution of mGluR, although this may simply be due to the 
fact that the previous tests have been conducted only in males, or alternatively, a 
failure to include sex as a factor in the final analysis. Only hippocampus-mediated 
contextual fear-conditioning was found to differ between sexes in this line, being 
severely impaired in ?????????males, but normal in ?????????females (Dachtler et 
al., 2011). There are reports that the alternative GluA1-independent plasticity that 
relies on nitric oxide pathway can compensate for the lack of GluA1 in the 
hippocampus more effectively in ?????????females (Phillips et al., 2008; Romberg 
et al., 2009), since neuronal nitric oxide activity is influenced by estrogen 
(d'Anglemont de Tassigny et al., 2009).
Figure 6. Effects of treatment with mGluR2/3 agonist on hyperactivity of Gria1????mice (III). Locomotor 
activities of naïve (A) and pre-handled (B) males and females WT and Gria1????mice after acute LY354740 
(15 mg/kg (AB) and 30 mg/kg (B), i.p.) administration during the first 30 min of exposure to a novel arena. Data 
are means ± SEM (n = 4–19).?p< 0.05, **p<0.01, ???p< 0.001 for the difference between genotypes after the 
same treatment; #p<0.05, ##p<0.01, ###p< 0.001 for the difference from vehicle-treatment of the same genotype; 
two-way ANOVA followed by Newman–Keuls post-hoc test. LY, LY354740; VEH, vehicle.
Glutamate may directly activate the hypothalamic-pituitary-adrenocortical axis, 
which is important in adaptation to stress. Females release more corticosterone 
than males and they generally exhibit less anxiety-related behaviour than their 
male counterparts (Handa et al., 1994; Rivier, 1999); they are also less 
susceptible to stress-induced hippocampal plasticity. On the other hand, the 
administration of LY354740 itself has not been reported to alter baseline (non-
stressed situation) corticosterone levels as the hypothalamus-pituitary-
adrenocortical axis is predominantly under the control of group I and group III 
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mGluRs (Johnson et al., 2001). Given that the antihyperactive effect of LY354740 
was absent in ????????? females, both naïve and pre-handled, the sexual
differences in LA after administration of this drug do not seem to be confined 
simply to differences in the stress responsivities between sexes.
5.1.2 ROLE OF HANDLING ON THE ANTI-HYPERACTIVE EFFECT OF 
THE MGLUR2/3 AGONIST (II I)
Different levels of LA were observed after administration of mGluR2/3 agonist 
LY354740 in pre-handled versus naïve mice. The two-fold reduction in LA 
achieved by LY354740 treatment in the non-handled male ?????????mice was 
markedly less evident after repeated handling (Fig.5, compare panel A and B) (III). 
It was shown that habituation to a stressor can normalize stress-induced IEG
expression (Ryabinin et al., 1999) but the effect of handling on the level of 
corticosterone can be variable (Hurst and West, 2010; Longordo et al., 2011;
Ryabinin et al., 1999). In ????????? mice the stress-induced increase in 
corticosterone level was similar to that seen in the WT mice (Fitzgerald et al., 
2010; Fumagalli et al., 2011); in the latter study, only male animals were used. 
5.2 EFFECTS OF DRUG-TREATMENTS IN OTHER TESTS SPECIFIC 
FOR SCHIZOAFFECTIVE SYMPTOMS
The ?????????mice were also challenged on two batteries of behavioural tests 
over the course of the chronic treatments that allowed extensive behavioural 
screening for schizoaffective symptoms (I, Fig. 1) (Takao et al., 2007). ?????????
mice showed disinhibited risk-taking and a highly exploratory phenotype, and 
social deficits, which were at least partially reversible by treatment with mood-
stabilisers (Table 8). Moreover, ????????? mice exhibited a slightly higher 
preference for sucrose and made more impulsive choices towards sucrose. The 
experimental design included repeated testing and required single housing in the 
second test battery. It was postulated that these conditions were not primarily 
governing the behaviour in these tests. This assumption was based on the similar
immobility times of ?????????mice and WT in despair-like tests of mice differently 
housed or similar LA of mice with previous testing history and those naïve to 
experimentation (I, see Results) (Voikar et al., 2005; Voikar et al., 2004).
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5.2.1 EFFECTS OF DRUG-TREATMENTS ON TESTS FOR ANXIETY-
LIKE AND GOAL-DIRECTED BEHAVIOUR (I)
Results from human behavioural pattern monitoring laboratory indicate that the 
high mobility and alteration of exploratory behaviour are characteristics of BPD 
manic and SCZ patients in comparison to healthy subjects (Henry et al., 2013;
Minassian et al., 2010; Perry et al., 2009; Young et al., 2007). When compared to 
SCZ patients, BPD manics display characteristic goal-directed activity: higher 
mobility with faster habituation and more interest in new objects (Perry et al., 
2010). Thereafter, the behavioural disinhibition pattern has been proposed to be 
an endophenotype of BPD that manifests across all phases of the disorder. In the 
present studies, ?????????mice undertook more center approaches and reacted 
more to a novel object both in the terms of frequency and time than WTs in the 
open field. These behaviours were sensitive to both lithium and valproate 
treatments (I, Fig.4). Additionally, a risk-taking phenotype of ?????????mice was 
observed in the EPM test, i.e. ?????????mice spent much more time in open arms, 
although no differences in open arm entries or the ratio of open versus closed 
entries were found between the genotypes (I, Fig.3). Treatment with topiramate 
reversed the risk-taking behaviour whereas valproate increased the latency of 
entering onto the open arms of ?????????mice, despite the fact that all stabilisers 
are recognized as possessing anxiolytic properties (Corbett et al., 1991; Khan and 
Liberzon, 2004).
5.2.2 EFFECTS OF DRUG-TREATMENTS ON TESTS FOR DESPAIR-LIKE
BEHAVIOUR (I)
FST and TST are the tests traditionally used for predicting the antidepressant-
like actions of drugs (Porsolt et al., 1977) but they have also been proposed as 
ways of modelling the increased vigour and goal-directed behaviour of manic 
episode of BPD (Flaisher-Grinberg and Einat, 2009). The increased goal-directed 
swimming behaviour observed in the ?????????mice in both FST and TST is in line 
with previous findings (Procaccini et al., 2011) and it was attenuated by treatment 
with valproate in the latter test (I, Fig.5). Unlike valproate, lithium affected WT 
animals by decreasing their immobility in FST (I, Fig.5). Both treatments markedly 
increased the habituation of ?????????mice to novel environment, but they had 
variable effects on swimming behaviour. Thus, the valproate effect was not solely 
a result of reduced locomotor performance and might be reflecting the differential 
sensitivity of other neurotransmitter systems to drugs in this particular task. The 
?????????behaviour in TST remained insensitive to acute escitalopram injection, 
unlike WT animals whose immobility became markedly reduced (Procaccini et al., 
2011), which might be related to differences in the functioning of the serotonergic 
system. The FST and TST are indeed widely used to test the drugs that affect the 
serotonergic system, but the levels of 5-HT of ?????????mice and WTs in various 
brain regions were very similar (Vekovischeva et al., 2004). On the other hand, it 
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was reported that immobility time in the FST test was dependent on the level of 
lithium in blood (Bersudsky et al., 2007). Thus, the lithium concentration might not 
have reached sufficient levels for there to be any observable effect on immobility in 
FST, at least in ?????????mice.
5.2.3 EFFECTS OF DRUG-TREATMENTS ON SOCIAL INTERACTION
(I)
It was found that ?????????mice more frequently than their WT counterparts
were interacting by reciprocal (simultaneously-initiated) contacts, but spent much 
less time engaged in the interaction. This deficit could be normalised by treatment 
with valproate (I, Fig.6). The unfamiliarity of the environment could contribute to 
deficits in the interaction time and frequency of social stimuli. In fact, deficits in the 
short-term habituation to the context of testing and altered attentional intensity 
might explain why ?????????mice were unable to direct appropriately their social 
encounters in an unfamiliar context, but in fact they increased their social 
interactions after habituation to the environment (Barkus et al., 2012b). In the 
present case, the elevated frequency of reciprocal contact might also reflect 
deficits in short-term habituation to social stimuli. Thus, relative importance of both 
environmental and social stimuli can be competitive (Barkus et al., 2012b) or 
complement each other in this case and lead to the observed deficits of social 
contacts. It has been reported that ????????? mice are deficient in short-term 
habituation processes and thus an increased attention to stimuli would even lead 
to enhanced long-term associations (Sanderson et al., 2009; Sanderson et al., 
2010). Inappropriate associations between stimuli may be attributable to 
hallucinations and delusions, phenomena encountered in the SAD (Gray, 1982;
Hemsley, 1994; Kapur, 2003).
5.2.4 EFFECTS OF DRUG-TREATMENTS ON HEDONISTIC
BEHAVIOUR (I)
The characteristic goal-directed and pleasure-seeking activity during manic 
episodes of BPD and reduced ability to experience pleasure in depression episode 
of BPD and in SCZ may represent abnormal reward processes. The voluntary 
responses of ????????? and WT mice were compared to two different natural 
rewarding stimuli, sucrose and RW. Both lines of mice ran similarly in the RWs,
but the ?????????mice, irrespective of drug-treatment, consumed more sucrose 
than WTs during six days of sucrose presentation (I, Fig.7). Interestingly, in the 
presence of RWs, the control WT mice reduced their consumption of sucrose (I,
Fig.7, S4 and S6 days). It was observed that rats, if given the opportunity to run,
will decrease the consumption of sucrose (Satvat and Eikelboom, 2006) as might 
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be the case with WTs in this study. In contrast, the ?????????mice continued to
consume sucrose at a level similar to that drunk before the RWs were introduced
into the cages. Thus, there was a differential sensitivity of ?????????and WT mice
to two natural rewarding stimuli, of which sucrose consumption revealed the 
genotype-specific difference. The mechanisms of these two stimuli seem to be 
different: the dopaminergic projection originating from the VTA is essential for 
sucrose intake (Shibata et al., 2009), whereas endocannabinoid disinhibition of 
VTA DA neurons has been claimed to play a role in the reward to voluntary 
running  (Dubreucq et al., 2013). It was interesting that the AMPA/NMDA receptor 
current ratio in VTA DA neurons was increased  in ?????????mice (Aitta-Aho et al., 
2012). Unexpectedly, treatment with standard mood-stabilisers, i.e. lithium and 
valproate, increased sucrose consumption in comparison to control treatment. In 
contrast, both drug-treatments increased running activity only in WT animals (I,
Fig.7BD). Thus, the rewarding responses were not consistently affected by the 
drugs.
5.2.5 ASSESSMENT OF DRINKING BEHAVIOUR OF GRIA???? MICE IN  
THE INTELLICAGE (UNPUBLISHED DATA)
5.2.5.1 ASSESSMENT OF HEDONISTIC BEHAVIOUR OF GRIA???? MICE
Free access to sucrose in the Intellicage revealed that ?????????mice and their 
WTs consumed sucrose similarly on the first two days. However, ?????????mice 
increased their consumption on the third and fourth days when the environment of 
the Intellicage became additionally enriched with RWs, whereas the WTs
remained at the same level of the consumption (Fig. 7; F3,43= 3.18, p=0.035). Both 
mouse lines avoided drinking quinine and the group RW activity was similar 
between the genotypes.
Monitoring of rodent behaviour in the Intellicage allows preservation of social 
settings of home cage (Galsworthy et al., 2005). On the other hand, in 
conventional cages if one wishes to assess the hedonistic behaviour, the mice 
have to be housed individually (Chapter 5.2.4). Thus, their consumption of sucrose 
may be influenced by the inevitable social isolation, and it has been reported that 
the isolation of rats can increase their sucrose consumption as compared to non-
isolated rats (Hall et al., 1997). The difference in the preference for sucrose of 
????????? mice in the presence of RWs in the conventional cages and the 
Intellicage emphasise the importance of controlling social settings when assessing 
the hedonistic behaviour of mice.
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Figure 7. Hedonistic behaviour of ????????? mice in the Intellicage. Voluntary sucrose consumption 
(number of licks) of ?????????mice and their WTs in the Intellicage environment enriched additionally with 
running wheels for the last two days. Data are means ± SEM (if larger than symbol) (n=5). *p<0.05 for the 
difference from the corresponding value on the day 1; #p<0.05 for the difference between the genotypes; two-
way repeated measures ANOVA followed by Bonferroni post-hoc test.
5.2.5.2 ASSESSMENT OF IMPULSIVE-LIKE BEHAVIOUR IN GRIA???? MICE
In patients with SAD, substance and alcohol abuse disorder are often 
comorbidities, sharing similar features such as impulsivity, novelty-seeking and 
disinhibition (Blanchard et al., 1999). Impulsivity may be a stable trait, but the 
behavioural expression of impulsivity is at its most prominent during manic or 
psychotic episodes (Swann et al., 2004). Impulsivity reflects poor regulation of the 
initiation of action, inability to wait for a reward and a deficiency in attention 
(Strakowski et al., 2009; Swann, 2009).
Drinking behavior was measured in the Intellicage to clarify whether the 
?????????mice would be able to perform the drinking protocol in the water and in 
the sucrose-quinine conditions. The total number of incorrect Vs (Fig.8A) and the 
total number of incorrect NPs (Fig.8B) of ???????? and WT mice were estimated 
under these conditions.
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Figure 8. Drinking behavior of ?????????mice during the experimental set-ups with either water or
sucrose-quinine conditions in the Intellicage. The number of incorrect visits (Vs) (A) and incorrect nose-
pokes (NPs) (B) are shown for each condition. Data are means ± SEM (if larger than symbol) (n=7-21). 
#p<0.05 for the difference between the genotypes; *p<0.05 for the difference from the corresponding value on 
the day 1; Wp<0.05 for the difference from the water condition. Linear Mixed Model followed by Bonferroni 
post-hoc test.
In the water conditions, the total number of incorrect Vs was higher in ?????????
mice than in WTs (Fig. 8A; F1,35=4.71, p<0.05) on the first training day. However,
the ????????? mice decreased the total number of incorrect NPs on the third 
training day (Fig. 8B; F2,35=5.58, p<0.01; using 3.42 as the average number of 
trials for 24-h). In the sucrose-quinine conditions, the ?????????mice made more 
mistakes on the third day as compared with the first one (Fig. 8AB; F2,51=4.79, 
p<0.05 and F2,51=3.54, p<0.05 for the total number of incorrect Vs and NPs, 
respectively). In addition, on the third training day they made more incorrect NPs 
than the WTs (Fig. 8B; F1,35=5.05, p<0.05; using 6.33 as the average number of 
trials for 24-h).
Then the specified incorrect behaviour of ?????????mice in the sucrose-quinine 
conditions was evaluated in each of the chambers (Fig. 9AB). Thus, ?????????mice 
made more mistakes than the WTs with respect to the sucrose-containing 
chamber (F3,400=6.61, p<0.0001 and F3,400=6.55, p<0.0001, for incorrect Vs and 
NPs, respectively) on the first training day (F6,400=4.35, p<0.0001 and F6,400=4.38, 
p<0.0001, for incorrect Vs and NPs, respectively), but the difference disappeared 
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on the other days. ?????????mice also made fewer mistakes related with the water-
containing chamber that preceded the quinine-containing chamber on the first and 
second training days (W2 on the Fig. 9AB). Both, ?????????mice and the WTs 
made a small number of the mistakes with respect to the quinine-containing 
chamber during all days. Thus, the presence of the aversive quinine solution might 
have stimulated the mice to search for a more palatable drink and promoted 
impulsive behaviour in the ?????????mice towards sucrose-containing chamber.
Figure 9: Drinking behaviour of ?????????mice in specific chambers with respect to sucrose-quinine 
solutions in the Intellicage. Incorrect visits (A) and incorrect nose-pokes (B) are shown for water- (W1 and 
W2), quinine- (Q) and sucrose- (S) containing chambers. Data are means ± SEM (if larger than symbol) (n=14-
21). #p<0.05 for the difference between the genotypes; Sp<0.05, qp<0.05 for the difference between behaviour
in water-chamber and behaviour in sucrose- or quinine-containing chambers, respectively. Linear Mixed Model
followed by Bonferroni post-hoc test. 
More mistakes that ?????????mice made on the first day of the training might 
be related to the hyperactivity of the ?????????mice when they are confronted with 
a novel situation (Fumagalli et al., 2011; Procaccini et al., 2011) and subsequent 
habituation to the testing context, or deficient short-term memory (Sanderson et 
al., 2009). In order to follow the protocol and obtain the next drink, an inhibitory 
response was required to reverse the learned behaviour and to switch attention to 
make a new nose-poke in the chamber that had been previously incorrect. This 
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may suggest that the ?????????mice lack the inhibitory control and this may be 
comparable with the impaired pre-pulse inhibition and novelty-seeking behaviour 
observed previously in ?????????mice (Wiedholz et al., 2008). Although the task 
was emotionally coloured (by the presence of attractive and unpleasant stimuli), 
this behaviour of Gria1????mice could not be attributed primarily to any enhanced 
propensity to favour consumption of sucrose, since the baseline consumption was 
similar in both ????????? and WT mouse lines (Fig.6, unpublished data)(I,
Fig.7)(Barkus et al., 2012b).
5.3 EFFECTS OF DRUG-TREATMENTS ON NOVELTY-INDUCED 
ACTIVATION OF BRAIN REGIONS OF GRIA???? MICE (II , III )
The baseline expression of the IEGs is very low and it rapidly increases upon 
stimuli that evoke neuronal activation (Procaccini et al., 2011). If one studies the 
patterns of IEGs expression then it is possible to create maps of the neuronal 
structures that underlie processing of stimuli (Kovacs, 1998). c-Fos expression 
was used as a cellular surrogate to map the pathways activated during aberrant 
locomotion of ?????????mice. 
          Table 9. Summary of the effects of drug-treatments on hippocampal c-Fos expression.
? reduced, ? no effect
The areas activated in these studies were the cortical, hippocampal, 
amygdaloid and septal regions that are normally reactive to novel situations and 
stress (Montag-Sallaz et al., 1999). The extremely striking activation of the 
hippocampus of ?????????mice (Procaccini et al., 2011) was confirmed in these c-
Fos studies. The studies involved two different levels across hippocampal dorso-
ventral axis in the analysis. In both ?????????and WT mice, novelty exposure led to 
greater c-Fos expression in dorsal hippocampal subfields, as compared to the 
ventral subfields (II, Fig. 2-4, III, Fig. 3-4). This confirms the differential 
involvement of dorsal and ventral subfields in performance of the spatial 
exploratory task (Fanselow and Dong, 2010). Secondly, all glutamate-modulating 
Treatment Dorsal hippocampus Ventral hippocampus
DG CA3 CA1 DG CA3 CA1
Lithium ? ? ? ? ? ?
Valproate ? ? ? ? ? ?
Topiramate ? ? ? ? ? ?
Lamotrigine ? ? ? ? ? ?
Perampanel ? ? ? ? ? ?
LY354740 (in males) ? ? ? ? ? ?
58
drug-treatments showed converging efficacy in blunting the excessive activation of 
dorsal hippocampus of ????????? mice (Table 9) (II, Fig. 2-4, III, Fig. 3-4). 
Treatment with perampanel (II, Fig. 4) and lamotrigine (II, Fig. 3) reduced the 
number of c-Fos-positive cells in all subfields of dorsal hippocampus of ?????????
mice, whereas the other mood-stabilisers reduced the reactivity of their dentate 
gyrus (DG) (except lithium) and CA3 subfields (II, Fig. 2). LY354740 (15mg/kg) 
particularly reduced the reactivity of dorsal CA1 of ?????????males (III, Fig. 3-4).
The subfield-specific reduction of c-Fos-positive cells by drug-treatment might be 
related to the preferential pathways that they suppress: either direct ones, from the 
entorhinal cortex to each subfield, or an indirect pathway, from the DG through 
CA3 to CA1 (Kesner et al., 2004).
With respect to the other brain regions, only the lateral septum displayed any
difference between the mouse genotypes. The response of amygdala was 
comparable between ?????????mice and WT mice (II, Tables 1-3, III, Table 1) and, 
in fact, the characteristic ‘anxiolytic-like’ induction of c-Fos expression after 
LY354740 in the central nucleus of amygdala was lacking (III, Table 1). The 
treatment with LY354740 would be expected to suppress the excessive excitatory 
neurotransmission on the intervening GABAergic neurons in basolateral nucleus of 
amygdala, which would then restore the inhibition that the lateral part of the central 
nucleus of amygdala (CeL) exerts on the medial output part (Linden et al., 2005;
Linden et al., 2004; Swanson et al., 2005). On the other hand, the effects of drug 
(as shown for amphetamine) on the c-Fos expression in the limbic regions might 
be precluded by the stress triggered by novel environment (Day et al., 2001; Day 
et al., 2005), since stress can inhibit the GABAergic neurons in the CeL.
In parallel to attenuation of hyperlocomotion in males exclusively (III, Fig. 2),
LY354740 reduced the reactivity of CA1 subfield of their dorsal hippocampus. It 
was notable that the CA1 reactivity of ?????????females to novelty as measured by 
c-Fos expression in the dorsal hippocampus (III, Fig. 4, Table 1) was lacking in 
contrast to the situation in their male counterparts. On the contrary, the ventral part 
of the lateral septum was more reactive in ?????????females than in the males, and 
this phenomenon was reversed by LY354740 treatment (III, Table 1).  
Treatment with mood-stabilisers, a selective AMPA antagonist and an 
mGluR2/3 agonist all blocked behavioural hyperactivity of ?????????mice with an 
accompanying reduction of excessive c-Fos expression in the hippocampus. This 
leads to the conclusion that strong reactivity of the hippocampus is likely to 
account for the behavioural hyperactivity encountered in the ?????????line and this 
can be attenuated by various drugs reducing glutamatergic transmission, pre-
and/or post-synaptically. The hippocampus of ?????????line is indeed vulnerable to 
different mild provocative situations, not only spatial novelty, as immobilisation 
stress has also increased expression of another IEG, activity-regulated 
cytoskeletal associated protein (Fumagalli et al., 2011).
Interestingly, the enhanced c-Fos expression of the dorsal hippocampus and 
???????????????????????????????????????? ???????????????????????????III, Fig. 5). c-Fos 
is one of IEGs and its induction is preceded by NMDA receptor activation and Ca2+
influx (Fleischmann et al., 2003). The global deletion of GluA1 may have caused 
an upregulation of Ca2+ binding proteins (Zhou et al., 2009) and this could be one 
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explanation for the excessive c-Fos activation. Interestingly, since the reference 
memory of ?????????mice has been reported to be intact (Sanderson et al., 2009)
and their acquisition of an instrumental stimulus response is faster (Barkus et al., 
2012b), one can speculate that c-Fos could be related with their better abilities to 
form long-term associations and not simply be only a marker of neuronal activity 
(Fleischmann et al., 2003). The formation of an internal representation about a
new space is a learning process and hippocampal LTP has been linked to novelty-
related exploration (Li et al., 2003). Thus in the ?????????line, the novelty exposure 
might promote the type of LTP that is independent of GluA1 subunit, for example 
as shown after theta-bursting pairing (Hoffman et al., 2002; Romberg et al., 2009).
Brain imaging studies have revealed that SCZ and BPD patients have reduced 
volumes of hippocampus and amygdala but enlargement of the ventricles (Arnone 
et al., 2009; Brambilla et al., 2001; Wright et al., 2000), although conflicting results 
exist in the latter case. The promotion of neuronal proliferation might contribute to 
the effects of antidepressants and mood-stabilisers, given the characteristic delay 
before the appearance of their therapeutic effects. Lithium, valproate and 
lamotrigine all have positive effects on neurogenesis (Manji et al., 2000; Leng et 
al., 2013) and are of great interest in various models of neurodegenerative disease 
due to their neuroprotective and neurotrophic actions (Alvarez et al., 1999; Chiu et 
al., 2013). There are reports that the ?????????mice exhibit decreased neuronal 
proliferation but increased survival of new neurons (Procaccini et al., 2011) in the 
adult hippocampal DG. The chronic treatments in the study might have 
differentially affected hippocampal neurogenesis and functional integration of new 
hippocampal neurons in the ?????????mice. Given the functional link between 
hippocampal neurogenesis and novelty-induced hyperactivity (Lemaire et al., 
1999), a restoration of hippocampal circuitry in the ?????????mice would result in 
better habituation to a novel environment. Interestingly, c-Fos, has also been
shown to regulate the expression of neurotrophic factors, and these could promote 
neuronal survival after excessive stimulation and protect neurons from 
excitotoxicity (Zhang et al., 2002).
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5.4 GENERAL DISCUSSION
5.4.1 COMPARISON OF GRIA???? MODEL WITH OTHER MOUSE 
MODELS OF RELEVANCE TO SCHIZOAFFECTIVE
SYMPTOMATOLOGY
The comparison of the ?????????phenotype with other genetic animal models of 
relevance to schizoaffective symptomatology (Table 5) is summarised below 
(Table 10). It is notable that the hyperactivity is the most commonly reported 
characteristic in these models and, as discussed, is the hallmark of psychotic 
disorders (Perry et al., 2010; Young et al., 2007).
The antagonism of NMDA receptors produces positive symptoms such as 
psychomotor agitation, negative symptoms such as anhedonia and social 
withdrawal, as well as cognitive symptoms. Similarly, the deficits observed in the 
Grin1hypo mice, with the reduced expression of the GluN1 subunit of NMDA 
receptors, are wide-ranging, including profound impairments in several cognitive 
tasks but may not mimic selectively schizoaffective phenotype (Table 5, 
10)(Barkus et al., 2012a). Instead, preferential deletion of GluN1 on cortical and 
hippocampal parvalbumin-positive interneurons (Belforte et al., 2010) but not on 
excitatory neurons in layer II/III of the medial prefrontal cortex and sensory cortices 
(Rompala et al., 2013) may represent a more comprehensive model. The 
??????????mice share some features with the SAD (Miyamoto et al., 2001), but 
there are some conflicting reports (see Boyce-Rustay and Holmes, 2006)(Table 5, 
10). For example, they do not exhibit deficits in pre-pulse inhibition as it has been 
claimed that both GluNR2A- and GluNR2B-containing receptors need to be 
affected for their disruption of this feature (Spooren et al., 2004). Kainate receptors 
are extensively expressed in hippocampus and are important for the control of 
inhibitory and excitatory transmission (Bureau et al., 1999; Fisahn et al., 2004).
???????? mice display behavioural alterations that mimic some of the behavioural 
symptoms of manic episode of BPD (Table 5, 10). In ???????? mice, the co-
occurrence of both mania- and depression- like behaviours suggests that these 
mice may have some face validity for bipolar-like behaviour (Table 5, 10).
Moreover, the deletion of GluD1 evoked changes in the expression of GluA1, 
GluK2 and glutamic acid decarboxylase 67 in amygdala and prefrontal cortex, 
which suggests that both excitatory and inhibitory synaptic neurotransmission are 
affected. The mice overexpressing Shank3 scaffolding protein at the PSD have 
been reported to display manic-like symptoms, seizures and increased 
hyperexcitability discharges on electroencephalogram (Han et al., 2013). Indeed, 
in ?????????mice some positive symptoms can be reversed by blockade of AMPA 
receptor with the antiepileptic perampanel and two other primarily antiepileptic 
drugs, valproate and topiramate. Together with aforementioned models, this 
supports the concept that there is an imbalance between excitatory and inhibitory 
transmission in favour of excitation in the pathogenesis of seizures (Magloczky 
and Freund, 2005) and a broad spectrum of neuropsychiatric disorders (Lisman et 
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al., 2008). It is now evident that epileptic and schizoaffective symptoms share 
many overlapping epidemiological, clinical, neuropathological and neuroimaging 
features (Cascella et al., 2009).
Table 10. Comparison of behavioural phenotypes between ?????????mice and previously described mouse 
models of schizoaffective symptomatology.
Behavioural 
symptom Grin1hypo ????????? ???????? ????????? Shank3 Tg ????????
Open field 
hyperactivity Yes Yes Yes Yes Yes Yes
Home cage 
hyperactivity Nt No Yes Nt Yes No
Less anxious or more 
risk-taking behaviour Nt Yes Yes Yes Nt Yes
More aggressive 
behaviour Nt Nt Yes Yes Nt No
Deficient social 
interaction Yes Yes Yes Yes Yes Yes
Increased locomotion
to amphetamine Nt Nt Yes Nt Yes No
Less despair-like
behaviour Nt Yes Yes No Yes Yes
Increased reward-
seeking behaviour Nt Nt Nt Nt Nt Yes
Deficient pre-pulse 
inhibition Yes No Nt Nt Yes Yes
Cognitive deficits Yes Yes Nt Nt Nt Yes
Impulsive-like 
behaviour Nt Nt Nt Nt Nt Yes
References Barkus et 
al., 2012a;
Duncan et 
al., 2006;
Mohn et 
al., 1999
Boyce-
Rustay and 
Holmes, 
2006;
Miyamoto 
et al., 2001
Shaltiel et 
al., 2008
Yadav et al., 
2012
Guilmatre et al., 
2014; Han et al., 
2013
Bannerman et al., 
2004; Fitzgerald 
et al., 2010;
Procaccini et al., 
2011; Sanderson 
et al., 2009;
Vekovischeva et 
al., 2004;
Vekovischeva et 
al., 2001;
Wiedholz et al., 
2008; Zamanillo 
et al., 1999;
Study I, III; 
unpublished data
Not tested (Nt)
There is a glutaminase-deficient mouse line which has reduced glutamate 
and elevated glutamine levels in the brain, and these animals exhibit hippocampal 
hypoactivity in imaging and electrophysiological studies, and the opposite
phenotype as seen with schizoaffective-like models (Gaisler-Salomon et al., 2009).
These data corroborate the present finding that there is a specific dysfunction in
the hippocampi of ?????????mice which contributes to behavioural abnormalities. 
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The presentation of novel environment induced activity in the hippocampus in both 
WT and G????????mice, but the latter animals reacted far more robustly. It is 
evident that the hippocampus acts as a comparator of inputs and stored 
information and triggers novelty-dependent firing of the VTA via polysynaptic 
pathway (Grace et al., 2007; Lisman and Grace, 2005). The VTA DA neurons 
combine novelty signals with information about the relative importance of stimuli 
and goals (through the limbic inputs of pedunculopontine tegmental nuclei 
projecting to VTA). The dopaminergic cells of the VTA project back to the 
hippocampus and induce dopamine release that facilitate the plasticity at the CA3 
inputs to CA1, and thus the entry of behaviourally significant information into long-
term memory (Bernabeu et al., 1997). On the other hand, a hyperdopaminergic 
state (through DA effects on D1 and D2 DA receptors) can selectively inhibit the 
continuing sensory inputs to CA1 from entorhinal cortex. A mismatch system of the 
CA1, a putative comparator of arriving sensory information from cortex and 
predictions from CA3, is disrupted and the whole loop is further enhanced (Lisman 
and Otmakhova, 2001). Thus the hippocampal – VTA loop in G????????mice may 
be dysfunctional, and G????????mice may be unable to filter sensory stimuli and 
habituate. Thus they would persistently perceive stimuli as novel and 
inappropriately attribute them with salience (Kapur, 2003). This may be related to 
abnormalities with the inhibition and attention, as the deficient PPI, working 
memory problems, impulsivity and enhanced reference memory are observed in 
G???????? mice. Furthermore, the VTA AMPA/NMDA receptor current ratio in 
G????????mice appeared to be increased (Aitta-Aho et al., 2012).
The complexity of symptomatology, polygenic nature and the lack of 
objective biomarkers prevent the modelling of neuropsychiatric diseases in 
rodents, but nonetheless the use of genetic rodent models is indispensable in 
clarifying the contribution of a gene to a characteristic phenotypic expression. It 
has been found that the hyperactivity appeared concomitantly with other 
behavioural abnormalities indicative of highly disinhibited behaviour of ?????????
mouse line. The co-occurrence of these behavioural abnormalities in ?????????
mice that are controlled by standard and investigational mood-stabilisers suggests 
that the lack of GluA1 protein all over the brain and in different stages of the 
development may be involved in the pathophysiological changes underlying 
schizoaffective symptomatology. The ?????????model may provide the evidence 
for the interaction between the glutamatergic and dopaminergic systems in the 
schizoaffective phenotype. It is noteworthy that aggressiveness as a correlate of 
irritability and easily provoked behaviour is not present in ????????? mice 
(Vekovischeva et al., 2004).
5.4.2 COMPARISON OF GLOBAL GRIA???? MODEL WITH THE
CONDITIONAL GRIA???? MODELS
Deletion of GluA1 in conventional ?????????mice is not cell-type specific, which 
means that its absence must have affected both main excitatory and inhibitory 
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neurotransmitter systems. In this respect, the complexity of the conventional 
phenotype may be the result of the large non-selective deletion, together with 
subsequent compensatory changes. Since the GluA1 subunit is particularly 
abundant on inhibitory GABAergic neurons (Catania et al., 1998; Leranth et al., 
1996), it was speculated that the inability of ?????????mice to activate NMDA-
mediated responses on interneurons would reduce GABAergic tone, disinhibit 
neurons and lead to abnormal neuronal activation (Fumagalli et al., 2011). The 
contribution of these systems and particular brain areas in driving specific 
abnormalities in ?????????mice have been recently addressed at the network and 
behavioural levels.
A mouse line with the temporal and site (cell)-specific ablation of GluA1 subunit 
has been created thus ablating the GluA1-containing receptors from principal 
(glutamatergic) neurons under the control of the CaM kinase II alpha promoter 
during late adolescence, the vulnerable stage for the onset of most of 
neuropsychiatric disorders (Inta et al., 2013). The behavioural deficits exhibited by
this mouse line include cognitive impairments, sensorimotor gating deficits and 
marked hyperlocomotion without the alterations of the levels of DA in striatum.
Therefore, deletion of GluA1 subunit-containing AMPA receptor from principal 
neurons but with a spared subunit in GABAergic interneurons, phenocopies all of 
the deficits seen in mice with global reduction of GluA1, except that this alteration
leaves sociability intact. There are reports that this deletion particularly affected 
the hippocampus, and induced a similar subcellular redistribution of GluA2 and 
upregulation of GluN2A and GluN2B as in ????????? mice (Inta et al., 2013;
Zamanillo et al., 1999).
The congruent behavioural phenotypes of mouse-lines with inducible and 
conventional deletion of GluA1 confirmed the vulnerability of the hippocampus. 
The important conclusions of these studies are as follows: (1) a hippocampal 
GluA1 deficiency exhibits an important schizoaffective-like phenotype and that (2)
the existence of a GluA1 deficiency on glutamatergic neurons has correlates to 
schizoaffective symptomatology, whereas its deficiency on GABAergic neurons 
may relate to depressive symptomatology (Vogt et al., 2014). Thus, the forebrain 
GluA1 ablation model was useful for differentiating contribution of glutamatergic 
and GABAergic neurotransmitter systems with regard to mood and psychotic
disorders as well.
Interestingly, the model with the spatially restricted GluA1 deletion shows that
hyperactivity persists despite the presence of intact GABAergic tone, and points to 
a major role of principal neurons of the hippocampus in triggering locomotor 
hyperactivity. In fact, virally-mediated introduction of GluA1 in the dorsal or 
complete hippocampus (to both principal and interneurons) was reported to 
abolish hyperactivity of ????????? mice (Freudenberg, 2009). In support of this 
view, mice lacking GluA1 only in forebrain interneurons show WT-like LA (Fuchs et 
al., 2007) but, in contrast, ????????? mice expressing GFPGluA1 in principal 
forebrain neurons remained hyperactive (Freudenberg et al., 2013a).
In summary, it seems likely that hippocampal AMPA dysfunction is a major 
contributor to behavioural hyperactivity of GluA1-/- mice. This is supported with 
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results of the present (III, Fig. 4) and a previous study of hyperactivity-attenuating 
effect by AMPA antagonists (Procaccini et al., 2011).
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6. SUMMARY AND CONCLUSIONS
1. The hyperactive phenotype of ????????? mice can be attenuated by 
targeting glutamatergic transmission. Two standard antiepileptic drugs, lithium and 
valproate, and the novel mood-stabilising anticonvulsants, topiramate and 
lamotrigine, all attenuated aberrant activity of Gria1????mice. Furthermore, the 
putative antipsychotic, mGluR2/3 agonist LY354740, and antiepileptic, the 
selective AMPA antagonist, perampanel demonstrated the same effect. Thus the 
control of glutamate release or the control of glutamate effects in the synaptic cleft 
or at the postsynaptic level appear to exert substantial antihyperactive effects in 
?????????mice. The ?????????mice seem to represent a model for the screening of 
the effects of novel drugs on the hyperactive behaviour relevant to psychotic 
disorders.
2. ????????? mice displayed disinhibited risk-taking, less-despair like and 
highly exploratory phenotype as well as social deficits, which were at least partially 
reversible with mood-stabilisers. ????????? mice exhibited a slightly higher 
preference for sucrose and made more impulsive choices towards sucrose. These 
tests are of particular relevance for other symptoms of psychotic disorders and 
they can be considered as important complements to locomotor activity test in 
assessments of drug efficacy in ?????????mice.  
3. All glutamate-modulating drug-treatments showed converging efficacy in 
blunting the excessive activation of the dorsal hippocampus of ?????????mice, as 
measured by c-Fos expression. The motor activity of ?????????mice correlated with 
dorsal hippocampal c-Fos expression. The highly-reactive hippocampus of 
?????????mice may account for behavioural hyperactivity. c-Fos is a sensitive 
molecular marker and it may prove to be a useful parameter in addition to 
behavioural screening evaluating for novel drug efficacy in ?????????mice.
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